US20110224260A1 - Catechol-based derivatives for treating or preventing diabetics - Google Patents
Catechol-based derivatives for treating or preventing diabetics Download PDFInfo
- Publication number
- US20110224260A1 US20110224260A1 US13/114,835 US201113114835A US2011224260A1 US 20110224260 A1 US20110224260 A1 US 20110224260A1 US 201113114835 A US201113114835 A US 201113114835A US 2011224260 A1 US2011224260 A1 US 2011224260A1
- Authority
- US
- United States
- Prior art keywords
- compound
- nmr
- catechol
- type
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 35
- 208000028867 ischemia Diseases 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000003085 diluting agent Substances 0.000 claims abstract description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 87
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 abstract description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 80
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 48
- 210000004369 blood Anatomy 0.000 description 37
- 239000008280 blood Substances 0.000 description 37
- 241000700159 Rattus Species 0.000 description 36
- 235000000346 sugar Nutrition 0.000 description 31
- 239000000243 solution Substances 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 102000004877 Insulin Human genes 0.000 description 24
- 108090001061 Insulin Proteins 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 229940125396 insulin Drugs 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 210000004351 coronary vessel Anatomy 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000000302 ischemic effect Effects 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 230000010410 reperfusion Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 0 [1*]C1=C([1*])C=C(C[Y]C(=[3*])[4*]([5*])[6*])C([2*])=C1 Chemical compound [1*]C1=C([1*])C=C(C[Y]C(=[3*])[4*]([5*])[6*])C([2*])=C1 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 235000004883 caffeic acid Nutrition 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 7
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 229940074360 caffeic acid Drugs 0.000 description 6
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 235000010603 pastilles Nutrition 0.000 description 6
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 5
- -1 3,4-methylendioxyphenyl Chemical group 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 229960004586 rosiglitazone Drugs 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 3
- JXRYDOZRPYFBKO-UHFFFAOYSA-N 3,4-dimethoxy-cinnamic acidmethyl ester Natural products COC(=O)C=CC1=CC=C(OC)C(OC)=C1 JXRYDOZRPYFBKO-UHFFFAOYSA-N 0.000 description 3
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910015845 BBr3 Inorganic materials 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 229910010084 LiAlH4 Inorganic materials 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 229940127003 anti-diabetic drug Drugs 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940127113 compound 57 Drugs 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- OCNYGKNIVPVPPX-HWKANZROSA-N methyl caffeate Chemical compound COC(=O)\C=C\C1=CC=C(O)C(O)=C1 OCNYGKNIVPVPPX-HWKANZROSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N C1COCO1 Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001347 alkyl bromides Chemical class 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005248 left atrial appendage Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
- ZBIRIFNPWDVHBV-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-n-butylprop-2-enamide Chemical compound CCCCNC(=O)C=CC1=CC=C2OCOC2=C1 ZBIRIFNPWDVHBV-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- NQQNJNJLUMWUOJ-UHFFFAOYSA-N C.CC(C)(C)N.CC(C)(C)N1CCCC1C#N.CC(C)(C)N1CCCCC1C#N.CN1CCN(C(C)(C)C)CC1.CN1CCN(C(C)(C)C)CC1.[CH3-] Chemical compound C.CC(C)(C)N.CC(C)(C)N1CCCC1C#N.CC(C)(C)N1CCCCC1C#N.CN1CCN(C(C)(C)C)CC1.CN1CCN(C(C)(C)C)CC1.[CH3-] NQQNJNJLUMWUOJ-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102000018692 Sulfonylurea Receptors Human genes 0.000 description 1
- 108010091821 Sulfonylurea Receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- NPPXMKKJYNRZBA-UHFFFAOYSA-N benzyl 3-(3,4-dihydroxyphenyl)propanoate Chemical compound C1=C(O)C(O)=CC=C1CCC(=O)OCC1=CC=CC=C1 NPPXMKKJYNRZBA-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- MAEVSPLUELJOMM-UHFFFAOYSA-N caffeic acid methyl ester Natural products COC(=O)C=CC1=CC=C(O)C=C1O MAEVSPLUELJOMM-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000002680 cardiopulmonary resuscitation Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1782—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to a compound having an antioxidant activity and the ability to prevent and treat diabetes or ischemia and the preparation thereof. More particularly, the present invention relates to a catechol-based derivative and the preparation thereof.
- Diabetes is the seventh leading cause of death (sixth-leading cause of death by disease) in the United States.
- Diabetes mellitus is a disease in which body does not produce and/or properly use insulin, a hormone that aids the body in converting sugars and other foods into energy.
- insulin is produced in the pancreas at the islets of Langerhans in response to an increase in glucose in the gut and/or blood. Insulin then acts in conjunction with the liver to control glucose metabolism in the body.
- diabetes is typically considered as a blood-sugar disease, diabetes may result in numerous life-threatening complications. For example, diabetes may lead to various microvascular diseases, such as coronary artery heart disease, retinopathy, nephropathy, and neuropathy.
- Diabetes mellitus is a medical disorder characterized by varying or persistent hyperglycemia (high blood sugar levels) resulting from the defective secretion or action of insulin.
- hyperglycemia high blood sugar levels
- the complication of diabetes can be controlled by maintaining the glucose level in advance to prevent or defer the development of illness. Therefore, it is worth to develop a powerful anti-diabetic drug for controlling the patient's glucose level within a normal range.
- diabetes mellitus There are several types of diabetes mellitus, which is classified based on their aetiology:
- Type 1 diabetes Insulin dependent diabetes mellitus (IDDM), commonly referred to as Type 1 diabetes, is an auto-immune disease. Type 1 diabetes occurs when body's immune system attacks and destroys beta cells in the islets of Langerhans in the pancreas. Beta cells normally produce insulin. If the beta cells are destroyed, no insulin can be produced, and glucose stays in the blood, where high level of glucose can cause serious damage to all organ systems in the body. Type 1 diabetes may affect as many as 1 million people in the United States.
- IDDM Insulin dependent diabetes mellitus
- Type 2 Non-insulin dependent diabetes mellitus (NIDDM), commonly referred to as Type 2 diabetes, is a metabolic disorder resulting from body's inability to produce sufficient insulin or properly use the insulin produced. Type 2 diabetes is characterized by peripheral insulin resistance with an insulin-secretory defect that varies in severity. Roughly 90 percent of all diabetic individuals in the United States suffer from Type 2 diabetes, which is usually associated with obesity and a sedentary lifestyle.
- NIDDM Non-insulin dependent diabetes mellitus
- the aetiology of this type of diabetes which is a secondary diabetes, can be traced to other diseases such as Hemochromatosis and Cushing's syndrome.
- Type 1 diabetes Under normal conditions, patients suffering from type 1 diabetes must take or inject insulin for body's necessary functions. This means undergoing multiple injections daily, or having insulin delivered through an insulin pump, and testing their blood sugar by pricking their fingers for blood about six or more times a day. Patients suffering from Type 2 diabetes often control their glucose level in the blood by taking anti-diabetic drug orally.
- the present oral anti-diabetic drugs are classified into five types.
- Sulfonylurea-based derivative This type of medicine binds to a sulfonylurea receptor existing in an ATP-dependent K + channel on the cell membrane of pancreatic beta cells, resulting in the inhibition of the K ATP channel and depolarization of membrane potential. As a result, voltage-gated Ca 2+ channels are opened, and the rise in intracellular calcium leads to increased secretion of (pro)insulin.
- Metformin is the most common drug in this class. Metformin stimulates a hepatic enzyme, AMP-activated protein kinase (AMPK), which enhances GLUT4 translocation to increase glucose uptake and utilization. In addition, Metformin increases the sensitivity of muscle cells to insulin, increasing muscle cell's ability to store glucose.
- AMPK AMP-activated protein kinase
- Thiazolidinedione-based derivatives this class of drugs binds to PPARs (peroxisome proliferator-activated receptors), a group of receptor molecules inside the cell nucleus, specifically PPAR ⁇ (gamma). This kind of drugs could enhance the insulin activity in the muscles and fatty tissues, as well as reduce the glucose synthesis in the liver and promote the conversion of blood sugar into the fatty acids.
- PPARs peroxisome proliferator-activated receptors
- PPAR ⁇ gamma
- ⁇ -glucosidase inhibitor This kind of drug is capable of inhibiting the activities of both pancreas ⁇ -amylase and intestinal ⁇ -glucosidase, so that the degradation of starch and carbohydrate is inhibited. Therefore, the glucose absorption into the intestine is reduced.
- Meglitinide-based derivatives This kind of drugs binds to 36 kDa receptor existing in an ATP-dependent K + channel on the cell membrane of pancreatic beta cells, leading to the inhibition of the ATP-dependent potassium channels in beta cells and opening of the calcium channels. The resulting calcium influx causes the cells to secrete insulin. These drugs act quickly when taken orally. Thus, it is recommended that these drugs be taken before meals to help control the rise in blood sugar levels after meals.
- ischaemic heart disease which is a disease characterized by reducing blood supply to the heart.
- Ischaemic hear disease often results in acute myocardial infarction (AMI), a congestive heart failure, arrhythmia, and sudden death. It is the most common cause of morbidity and mortality in most industrial countries. According to statistics published by the United State government in 2001, death resulting from ischaemic heart disease accounts for 20% of total death numbers (approximately 60 million deaths per year) (Myerburg R J., Cardiovasc Electrophysiol., 12, 369-381, 2001), wherein the majority of the deaths is caused by sudden death of people falling ill for first time.
- Another factor is to minimize the size of myocardial infarction due to ischemia or ischaemia-reperfusion.
- the degree of recovery depends on the extent of injury of the cardiac muscle after ischaemia or ischaemia-reperfusion.
- the standard protocols for treating acute myocardial infarction include giving patients thrombolytic agent or performing percutaneous transluminal coronary angioplasty (PTCA). These treatments could immediately recover the blood flow to the heart. Although such treatments are helpful in preventing further deterioration of the ischaemic cardiac muscles, they may lead to complications. Particularly, in high risk populations, surgery may lead to prolonged contractile dysfunction (or stunning), perioperative myocardial infarction, and cardiac failure. Therefore, there still exists a need for novel auxiliary treatments to be used in conjunction with the perfusion therapy to prevent injuries to the cardiac muscle caused by ischaemia or ischaemia-reperfusion.
- the present invention provides a series of catechol-based derivatives, which promotes blood flow in the coronary artery, suggesting that they are capable of preventing or treating injuries of the cardiac muscles caused by ischaemia or ischaemia-reperfusion.
- Embodiments of the present invention not only solves the problems described above, but also is easy to implement.
- the present invention provides a novel catechol-based derivative, which includes one selected from the group consisting of a compound of a formula (I), a pharmaceutical acceptable salt thereof, and a solvate thereof,
- R 1 and R 2 are independently selected from the group consisting of H, —OR, —NO 2 , —NH 2 , and a halogen;
- R in the —OR is one selected from the group consisting of H, (C 1 -C 6 )alkyl, (CH 2 ) n Ph, SO 3 ⁇ , and Ar;
- R 3 is one of O and S;
- R 4 is N;
- X and Y are selected from the group consisting of alkyl, alkenyl, alkynyl, and —OCH 2 —;
- R 5 is one selected from the group consisting of H, (C 1 -C 15 )alkyl, (CH 2 ) n Ar and Ar;
- R 6 is one of H and (C 1 -C 6 ) alkyl and n is an integer from 1 ⁇ 3.
- the two R 1 substituents on the benzene ring form the following structure:
- R 5 -R 4 -R 6 fauns a cyclic structure selected from the group consisting of:
- n is an integer from 2-6.
- Ar is capable of being substituted by one selected from the group consisting of
- R 7 , R 8 , R 9 are selected from the group consisting of H, —OH, —OCH 3 , —NO 2 , —NH 2 , —NH 3 + , and a halogen; and X— represents an organic base or an inorganic base.
- a pharmaceutical composition for preventing or treating diabetics comprising a catechol-based derivative described above and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier is provided.
- the pharmaceutical composition is used for preventing and treating damages of kidney, brain and heart resulting from an obstruction of a blood vessel (i.e., ischemia).
- a blood vessel i.e., ischemia
- a pharmaceutical composition for preventing or treating ischemia comprising a catechol-based derivative described above and one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.
- the pharmaceutical composition is used for preventing and treating damages of kidney, brain and heart resulting from an obstruction of a blood vessel (i.e., ischemia).
- a blood vessel i.e., ischemia
- FIG. 1 shows results from intravenous glucose tolerance test (IGTT) in response to the treatment with compound 370G;
- FIG. 2 shows areas at risk of ischemia after the coronary artery is ligated
- FIG. 3 shows the ratios of the cardiac infract size in response to treatment with 370G at different doses.
- the present invention discloses a series of catechol-based derivatives.
- the catechol-based derivatives having the formula (I) may be prepared by reacting caffeic acids with alcohols in the presence of an inorganic acid as a catalyst, or alternatively by refluxing the compound containing RNH 2 functional groups with the acyl chloride formed by reacting 3(3,4-methylendioxyphenyl)-propenoic acid with dichloromethane (CH 2 Cl 2 ) and thionyl chloride (SOCl 2 ).
- Reactants for the present invention could be prepared by esterification to convert the original functional group into an ester group.
- methyl ester may be prepared by refluxing a mixture of p-toluenesulfonic acid (TsOH) and 2,2-dimethoxypropane in methanol. If another ester is desired, it could be prepared by refluxing the mixture of p-toluenesulfonic acid (TsOH) and 2,2-dimethoxypropane in a desire alcohol.
- the resultant ester may be dissolved in tetrahydrofuran (THF) and reduced with LiAlH 4 to the corresponding alcohol.
- the resultant alcohol may be dissolved in tetrahydrofuran (THF), deprotonated with sodium hydride (NaH), and reacted with an alkyl bromide (RBr) to produce an ether compound.
- Methyl ester is prepared by putting caffeic acid (compound (I) in Scheme 1) in a glass flask, followed by the addition of TsOH, 2,2-dimethoxypropane and the methanol. The resultant solution is heated to reflux to produce methyl ester of caffeic acid.
- Other esters (other than methyl esters) may be prepared by refluxing the mixture of compound 1 and TsOH in a desired alcohol as a solvent. After the reaction, the solvent is removed and the residue poured into water. The ester is extracted with ethyl acetate. The extract is neutralized and purified with a column chromatography to afford ester derivative (A).
- esters (A) thus prepared are shown in Table 1.
- ester derivative (A) is dissolved in methanol and hydrogenated in the presence Pd—C as a catalyst to afford a saturated ester. After hydrogenation, the catalyst was removed by filtration and washed with methanol to produce the corresponding saturated ester derivative (B).
- Various ester (B) thus prepared are shown in Table 2.
- a derivative (C) is dissolved in CH 2 Cl 2 , reacted with BBr 3 at approximately ⁇ 30° C., and then the reaction is terminated with the addition of ice water.
- the resultant solution is extracted with CH 2 Cl 2 .
- the organic extracts are combined, dried, filtered, and evaporated.
- the residue is purified with column chromatography to produce derivative (D). Examples of derivative (D) are shown in Table 4.
- Dissolve the type-D derivatives in the methanol which saturates with hydrogen gases in the presence of Pd—C as a catalyst to give a reactant, followed by filtering the catalyst and washing with methanol to obtain a corresponding type-E derivative.
- Dissolve the type-E derivatives in a two-neck bottle containing the pyridine and react the resultant solution with Ac 2 O at the room temperature for overnight, and then the reaction is terminated with the addition of ice water.
- the resultant solution is further extracted by CH 2 Cl 2 , wherein the organic phase is collected to remove water, to be filtered, to be condensed and perform a column chromatography. Accordingly, type-H derivatives could be obtained, please referring to Table 5.
- the type-D derivatives as shown in Table 5 could be obtained with 65 ⁇ 85% yield (such as 638A-I). If selecting a ferrulic acid and 2-phenylethanamide to substitute the mentioned compounds, the compound 640 could be obtained.
- the compound 57 serves as a starting material to react respectively with C 2 H 5 Br, C 3 H 7 Br, and C 4 H 9 Br containing an alkyl bromide to substitute CH 3 I, so as to synthesize the respective compounds 59-61 of the type-F derivatives as shown in Table 7.
- Type-F derivatives Com- Com- Com- Com- pound R pound R pound R pound R 58 CH 3 59 C 2 H 5 60 C 3 H 7 61 C 4 H 9
- Type-H derivatives Com- pound R R 1 R 2 639A —(CH 2 ) 2 Ph CH 3 CH 3 639B —(CH 2 ) 2 Ph Ac Ac 639C —(CH 2 ) 2 Ph Ac ⁇ grave over ( ) ⁇ H 640 —(CH 2 ) 2 Ph CH 3 H
- the pharmaceutical composition of the present invention could be in the form of a liquid or a patch directly pasting on local wound area with all kinds of excipients, carriers, and diluents if necessary.
- the formulation can be in the form of pastilles, tablets, and capsules with adding a binder, such as starch or sodium carboxymethyl cellulose according the conventional methods.
- the formulation also can be in the form of the sustained-release pastilles or capsules by adding the sustained-release reagents.
- the present invention provides a manufacturing process of the present formulation to produce double pastilles or mixture particles with different release level based on the desired particle size, or alternatively to produce an formulation by encapsulating the particle having various size with immediate release film-coated pastilles, slow release film-coated pastilles, and anti-acidity film-coated pastilles.
- the first aspect of the present invention is to provide a compound for preventing or treating the diabetics and the implications thereof, wherein the compound is the catechol-based derivatives.
- the present invention further provides a pharmaceutical composition which comprises a therapeutically effective amount of the compound and the pharmaceutical acceptable carriers or the excipients.
- the pharmacological data of the compounds of the present invention is evaluated in vivo.
- Male Wistar rats are provided from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan), each of whose weight is about 200-250 grams, and the average age thereof is above 8 weeks. They were housed under conditions of constant temperature (25 ⁇ 1° C.) and controlled illumination (light time and dark time are respectively 12 hours). Food and water were available.
- Streptozocin-induced type 1 diabetic rats the male Wistar rats of 8 weeks age undergo a starvation for 72 hours, followed by anaesthetizing the rats by injecting with 30 mg/kg pentobarbital into the abdominal cavity. After the rats fall asleep, 60 mg/kg streptozotocin (STZ) is administrated by an intravenous injection. After a week, phlebotomize and obtain a value of blood sugar by a glucose kit, wherein the glucose kit is further analyzed by Biosystem S.A., Barcelona Spain, BST330. While the value of the blood sugar is greater than 400 mg/dL and the typical three symptoms, eating more, drink more, micturition occur, it is deemed as Type 1 Diabetic rats.
- Insulin-induced type 2 diabetic rats the abdominal cavity of the male Wistar rats of 12 weeks age are injected with 0.5 IU/kg long-term insulin (MonotardR HM) three times a day for fourteen days. Then, the 10 mg/kg tolbutamide, an anti-diabetic drug of sulfonylurea class, is injected into the abdominal cavity. Phlebotomize 0.1 ml blood respectively at the preadministration and the postadministration of sixty minutes, and calculate the reduced value of the blood sugar. If the variation of the ability of lowering blood sugar is less than 10%, which is deemed as the type II (insulin resistance) diabetes rat.
- the rats to be experimented should undergo a starvation for 8-12 hours overnight. Next day, the rats are anesthetized with 30 mg/kg pentobarbital by injecting into the abdominal cavity. After the rats fall asleep, fix the rats on the board with the rubber band. Open the groin, find the veins, bleed 0.1 ml blood from an empty stomach, and then feed the medicine into the body of the rats by taking orally. After 90 minutes, bleed and perform a centrifugation (13,000 rpm, 5 minutes) to separate the serum and the plasma. Take the 10 ⁇ l supernatant of the serum and add 1 ml reagent of the glucose kit thereinto by gently mixing.
- the principal of the glucose kit depends on the level of the glucose being oxidized into glucuronic acid and hydrogen peroxide, which exhibits different levels of red color.
- the value of the blood sugar (mg/dL) is calculated by comparing the level of redness with contrasting the standard curve.
- Each of the male Wistar rats weighs about 200-250 grams, and is anesthetized with 25 mg/kg pentobarbital and 16 mg/kg heparin by injecting into the abdominal cavity. After falling asleep, separate the cervical vertebra and immediately take the heart out hanging on the constant pouring pressure circulation instrument (Langendorff, AD Instruments Pty Ltd, ML870B2) and fill a 37° C.
- pouring solution of 95% of oxygen and 5% of carbon dioxide with the artery (119.7 mM NaCl, 23.8 mM NaHCO 3 , 5.6 mM glucose, 1.2 mM CaCl 2 , 1.1 mM MgCl 2 , 0.3 mM NaH 2 PO 4 , and 5.0 mM KCl), which washes the heart and clean out the blood water by pouring in a reverse direction.
- the rate of the reverse pouring is 10 ml/min, followed by maintaining the pouring pressure of the coronary artery at 80 mmHg. After balancing for thirty minutes, measure the rate of the pouring solution flowing in the heart, and observe the change of the rate the pouring solution flowing in the heart while the testing drug is added.
- the grown-up male rats having the weight of 250 ⁇ 300 grams are anesthetized with 1.25 g/kg urethane by the abdominal cavity injection. After anaesthetization, cut the trachea, connect with the artificial respirator (Harvard Rodent Ventilator Model 983), give 15 ml/kg of the tidal volume, and control the respiratory rate at 668 strokes/min, followed by cutting off both sides of the vagus immediately. After the intubation of the right arterial carotis, it is connected to the pressure converter (Statham P23XL transducer) so as to monitor the changes of systemic blood pressure.
- the pressure converter Statham P23XL transducer
- the rats' four limbs are connected to the silver electrode, so as to record the changes of the electrocardiogram (ECG).
- ECG electrocardiogram
- Blood pressures, heartbeats and electrocardiogram curves are recorded and analyzed by the software (MacLab data acquisition system, AD Instrument Pty, Castle Hill, NSW, Australia).
- the acute cardiac muscle ischaemia is caused by pushing the loop passed by a silk yarn with a hemostat downwards to be stabilized. Then, unclamp the hemostat and uplift the loop to perform a reperfusion of the coronary artery being ligated by the silk yarn. While the flow of the coronary artery is successively blocked, the ischaemic area should appear the cyanosis, where some indicators of the cardiac ischaemia could be observed, including the lowering pressure of the coronary artery and the changed electrocardiography (R wave broadens, and ST section raises), which is achieved by means of the same strength of pushing downwards during each surgery.
- the rat without administrating the drug and performing an ischaemia and an ischaemia/reperfusion is regarded as the sham group.
- the rundown of the ischaemia and the ischaemia/reperfusion of the present test are as follows.
- the rat does not die from the cardiac arrhythmia, push the loop downwards again to block the blood flow after the reperfusion is finished. Inject the approximately 2 ml, 1% methylene blue into the ischaemic area via a jugular vein, where the non-ischemic area is dyed as purple and the ischemic area or area at risk is retained as red. Subsequently, the heart is immediately took out and washed by the physiological salt solution to remove the connective tissue of the atrium and the surplus water. Cut the undyed ischemic area and weight the total ventricle to calculate the ischemic area of the ventricle.
- the living cells are able to produce the dehydrogenase, which could reduce TTC to a crimson formazan precipitate, whereas the dead cells are unable to produce dehydrogenase, which decolor the formazan as a gray precipitate. Cut and weight the gray infraction area and calculate the ratio.
- Table 10 shows the result of the changes of blood sugar in the treatment of the compound 370G among the normal rats and the diabetic rats.
- This test is performed by orally administrating the compound 370G. It is found that the phenomenon of reducing the blood sugar are shown on the normal rats and the type II diabetics rats when they are orally administrated the compound 370G a catechol-based derivative, with the dosage ranging from 0.05 to 1.0 mg/kg, wherein *P is smaller than 0.05 and the blank solution is orally administrated as a control contrast.
- Table 14 shows the comparative result of the changes of blood sugar in the treatment of the compound 370G at the preadministration and the postadministration. It is found that the compound 370 G has the strongest effect for reducing the blood sugar on the normal rat while having the weakest effect on the type I diabetic rat.
- Table 11 shows the result of the changes of the insulin's concentration in the treatment of the compound 370G at the preadministration and the postadministration. After orally administrating the compound 370G with the dosage of 1.0 mg/kg, the secretion of insulin can be increased in 60 minutes (*P ⁇ 0.05), which suggested that the compound 370G for reducing the blood sugar may be associated with enhancement of the secretion of insulin.
- the compound 370G for reducing the blood sugar involves another kind of mechanism associated with the blood sugar reduction in addition to enhance the release of insulin.
- Rosiglitazone is a kind of insulin sensitizer.
- the compound 370G and Rosiglitazone are orally administrated into the type II diabetic rats for 90 minutes, and then detect the plasma glucose concentration. It is found that the type II diabetic rats having the insulin impedance have the similar effect for reducing the blood sugar with the commercial insulin sensitizer.
- FIG. 1 shows the result of the changes of the intravenous glucose tolerance test (IGTT) in the treatment of the compound 370G. It is found that the glucose availability of the rats is raised in the oral administration of the compound 370G with the dosage of 0.5 mg/ml/kg as compared the results of the control contrast (*P ⁇ 0.05), which is administrated with 1000 mg/kg glucose for 30 minutes by an intravenous injection.
- IGTT intravenous glucose tolerance test
- Table 13 shows the result of the survival rate after orally administrating the compound 370G into the type I diabetic rats.
- Table 13 is a safety evaluation, wherein the type I diabetic rats are respectively orally administrated with the compound 370G at the dosage of 10 mg/kg and 30 mg/kg. After seven days, it is found that the administration of the compound 370G at the respective dosage of 10 mg/kg and 30 mg/kg do not affect the survival rate of the rats.
- the present compounds of the catechol-based derivatives exhibit good effect on reducing the blood sugar for the normal and the diabetic rats at the lower dosages ranging from 0.05 to 1 mg/kg, whereas the survival rate of the above rats are not influenced at the higher dosages of respective 10 mg/kg and 30 mg/kg. Therefore, this kind of catechol-based derivatives could be developed to be a potential anti-diabetics drug.
- the second aspect of the present invention is to provide a catechol-based derivative for preventing and/or treating ischemia and the complication thereof, and to provide a pharmaceutical composition comprising the above derivative, including the therapeutically effective amount of the catechol-based derivative selected form the group consisting of the formula (I) and a pharmaceutical acceptable carrier or an excipient.
- Table 15 and 16 respectively show the result of the coronary flow rate in the treatment of the catechol-based derivatives. It is found that the respective compound 370G, 638J, 640, 6381, 642A, 642B, 639B, and 639C are capable of increasing the coronary flow rate of Wistar rats, which suggests that this kinds of catechol-based derivatives are capable of increasing the coronary flow rate and reducing the injury areas of cardiac muscles resulting from the myocardial ischemia-reperfusion.
- FIG. 2 shows the results of the ischemic areas at risk after the coronary artery is ligated.
- the coronary artery of the rat heart is ischaemic by ligating for 45 minutes, and the blood vessel is unclamped for the reperfusion for two hours, wherein some tissues of the local ischemic area will be deteriorated.
- the ratio variations thereof are non-obvious.
- the ratio in the treatment of DMSO, PEG, and the compound 370G at the dosages of 10 ⁇ 6 mg/kg, 10 ⁇ 5 mg/kg, and 15 mg/kg are respectively 38.7 ⁇ 1.0%, of 36.4+1.3%, of 39.1 ⁇ 1.9%, 36.7 ⁇ 2.3%, and 41.1 ⁇ 1.3%).
- FIG. 3 shows the ratios of the cardiac infract size in the treatment of 370G at the different dosages.
- the ratio of both DMSO and PEG, which serve as the contrast agents, are respectively 80.2+1.2% and 80.1 ⁇ 1.0%.
- the infract size is reduced to 70.9 ⁇ 2.8 in the oral administration of the compound 370G at the dosage of 10 ⁇ 6 mole/kg (approximately 0.28 mg/kg); the infract size is reduced to 68.8 ⁇ 2.9% in the oral administration of the compound 370G at the dosage of 10 ⁇ 5 mole/kg (approximately 2.8 mg/kg); and the infract size is reduced to 62.8 ⁇ 1.8% in the oral administration of the compound 370G at the dosage of 15 mole/kg. Therefore, the mentioned results show the distinguishable variation as compared with the contrast agents, wherein * represents p ⁇ 0.05, ** represents p ⁇ 0.01, and *** represent p ⁇ 0.001).
- the respective compounds 638J, 640, 638I, 642A, 642B, 639B, and 639C have the similar effect of the compound 370G for preventing the heart or other tissues damaging resulting from the myocardial infraction.
- the catechol-based derivatives of the present invention are indeed capable of preventing or treating the diabetics and the ischaemic diseases and the implications thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetes and ischemia, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.
Description
- This application is a Divisional Application of the Non-provisional application Ser. No. 12/368,167 filed Feb. 9, 2009, which is a Continuation-in-part Application of the International Application PCT/CN2006/001991 filed Aug. 7, 2006. The entire contents of these prior applications are hereby incorporated by reference.
- The present invention relates to a compound having an antioxidant activity and the ability to prevent and treat diabetes or ischemia and the preparation thereof. More particularly, the present invention relates to a catechol-based derivative and the preparation thereof.
- There are currently 15.7 million people or 5.9% of the population in the United States who suffer from diabetes mellitus. Each day approximately 2,200 people are diagnosed with diabetes and roughly 798,000 people will be diagnosed this year. Diabetes is the seventh leading cause of death (sixth-leading cause of death by disease) in the United States.
- Diabetes mellitus, more commonly known as diabetes, is a disease in which body does not produce and/or properly use insulin, a hormone that aids the body in converting sugars and other foods into energy. In a non-diabetic individual, insulin is produced in the pancreas at the islets of Langerhans in response to an increase in glucose in the gut and/or blood. Insulin then acts in conjunction with the liver to control glucose metabolism in the body. While diabetes is typically considered as a blood-sugar disease, diabetes may result in numerous life-threatening complications. For example, diabetes may lead to various microvascular diseases, such as coronary artery heart disease, retinopathy, nephropathy, and neuropathy. Diabetes mellitus is a medical disorder characterized by varying or persistent hyperglycemia (high blood sugar levels) resulting from the defective secretion or action of insulin. Nowadays, the complication of diabetes can be controlled by maintaining the glucose level in advance to prevent or defer the development of illness. Therefore, it is worth to develop a powerful anti-diabetic drug for controlling the patient's glucose level within a normal range.
- There are several types of diabetes mellitus, which is classified based on their aetiology:
- 1. Type 1: Insulin dependent diabetes mellitus (IDDM), commonly referred to as Type 1 diabetes, is an auto-immune disease. Type 1 diabetes occurs when body's immune system attacks and destroys beta cells in the islets of Langerhans in the pancreas. Beta cells normally produce insulin. If the beta cells are destroyed, no insulin can be produced, and glucose stays in the blood, where high level of glucose can cause serious damage to all organ systems in the body. Type 1 diabetes may affect as many as 1 million people in the United States.
- 2. Type 2: Non-insulin dependent diabetes mellitus (NIDDM), commonly referred to as Type 2 diabetes, is a metabolic disorder resulting from body's inability to produce sufficient insulin or properly use the insulin produced. Type 2 diabetes is characterized by peripheral insulin resistance with an insulin-secretory defect that varies in severity. Roughly 90 percent of all diabetic individuals in the United States suffer from Type 2 diabetes, which is usually associated with obesity and a sedentary lifestyle.
- 3. Specific type: The aetiology of this type of diabetes, which is a secondary diabetes, can be traced to other diseases such as Hemochromatosis and Cushing's syndrome.
- 4. Gestational Diabetes
- Under normal conditions, patients suffering from type 1 diabetes must take or inject insulin for body's necessary functions. This means undergoing multiple injections daily, or having insulin delivered through an insulin pump, and testing their blood sugar by pricking their fingers for blood about six or more times a day. Patients suffering from Type 2 diabetes often control their glucose level in the blood by taking anti-diabetic drug orally. The present oral anti-diabetic drugs are classified into five types.
- 1. Sulfonylurea-based derivative: This type of medicine binds to a sulfonylurea receptor existing in an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells, resulting in the inhibition of the KATP channel and depolarization of membrane potential. As a result, voltage-gated Ca2+ channels are opened, and the rise in intracellular calcium leads to increased secretion of (pro)insulin.
- 2. Biguanide-based derivative: Metformin is the most common drug in this class. Metformin stimulates a hepatic enzyme, AMP-activated protein kinase (AMPK), which enhances GLUT4 translocation to increase glucose uptake and utilization. In addition, Metformin increases the sensitivity of muscle cells to insulin, increasing muscle cell's ability to store glucose.
- 3. Thiazolidinedione-based derivatives: this class of drugs binds to PPARs (peroxisome proliferator-activated receptors), a group of receptor molecules inside the cell nucleus, specifically PPARγ (gamma). This kind of drugs could enhance the insulin activity in the muscles and fatty tissues, as well as reduce the glucose synthesis in the liver and promote the conversion of blood sugar into the fatty acids.
- 4. α-glucosidase inhibitor: This kind of drug is capable of inhibiting the activities of both pancreas α-amylase and intestinal α-glucosidase, so that the degradation of starch and carbohydrate is inhibited. Therefore, the glucose absorption into the intestine is reduced.
- 5. Meglitinide-based derivatives: This kind of drugs binds to 36 kDa receptor existing in an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells, leading to the inhibition of the ATP-dependent potassium channels in beta cells and opening of the calcium channels. The resulting calcium influx causes the cells to secrete insulin. These drugs act quickly when taken orally. Thus, it is recommended that these drugs be taken before meals to help control the rise in blood sugar levels after meals.
- In addition, earlier studies showed that several catechol-containing natural products, such as caffeic acid (Hsu F L, Chen Y C, Cheng J T et al., Planta Med, 66(3), 228-230, 2000), extracts of propolis from north China (Fuliang H U, Hepburn H R et al., Pharmacol Res, 51(2), 147-152, 2005), extracts of propolis from Brazil (Matsui T, Ebuchi S, Fujise T et al, Biol Pharm Bull, 27(11), 1797-1803, 2004), capsaicin (Tolan I, Ragoobirsingh D, Morrison E Y., Phytother Res, 18(1), 95-96, 2004), curcumin (Mahesh T, Sri Balasubashini M M, Therapie 2004, 59(6): 639-644), and the like, are effective in lowering blood sugar.
- Diabetes is often associated with cardiovascular diseases, particularly, ischaemic heart disease, which is a disease characterized by reducing blood supply to the heart. Ischaemic hear disease often results in acute myocardial infarction (AMI), a congestive heart failure, arrhythmia, and sudden death. It is the most common cause of morbidity and mortality in most industrial countries. According to statistics published by the United State government in 2001, death resulting from ischaemic heart disease accounts for 20% of total death numbers (approximately 60 million deaths per year) (Myerburg R J., Cardiovasc Electrophysiol., 12, 369-381, 2001), wherein the majority of the deaths is caused by sudden death of people falling ill for first time. In addition, it is estimated that there are approximately 110 million Americans suffering from AMI in 2001, including new cases and recurrence cases. Many patients noted above develop subsequent complications, which cause heart failures and deaths. In recent years, the increase in aging population and other common complications, such as the obesity and the diabetes, puts a greater burden on public health budgets for ischaemic heart disease. Therefore, how to effectively minimize ischemia and reduce injuries associated with reperfusion of ischaemic hearts has become an important medical issue.
- Two key factors impact the outcome of treating ischaemic heart diseases. One is to take actions to prevent or minimize cardiac arrhythmia. Most patients suffering from acute myocardial infarction die from arrhythmia; some of these patients may survive because of spontaneous recovery of the heart rhythm or after a cardiopulmonary resuscitation (CPR). However, the success in the treatment for cardiac arrest has been dismal in the past thirty years.
- Another factor is to minimize the size of myocardial infarction due to ischemia or ischaemia-reperfusion. The degree of recovery depends on the extent of injury of the cardiac muscle after ischaemia or ischaemia-reperfusion. The standard protocols for treating acute myocardial infarction include giving patients thrombolytic agent or performing percutaneous transluminal coronary angioplasty (PTCA). These treatments could immediately recover the blood flow to the heart. Although such treatments are helpful in preventing further deterioration of the ischaemic cardiac muscles, they may lead to complications. Particularly, in high risk populations, surgery may lead to prolonged contractile dysfunction (or stunning), perioperative myocardial infarction, and cardiac failure. Therefore, there still exists a need for novel auxiliary treatments to be used in conjunction with the perfusion therapy to prevent injuries to the cardiac muscle caused by ischaemia or ischaemia-reperfusion.
- The present invention provides a series of catechol-based derivatives, which promotes blood flow in the coronary artery, suggesting that they are capable of preventing or treating injuries of the cardiac muscles caused by ischaemia or ischaemia-reperfusion. Embodiments of the present invention not only solves the problems described above, but also is easy to implement.
- In order to overcome the drawbacks in the prior art, the present invention provides a novel catechol-based derivative, which includes one selected from the group consisting of a compound of a formula (I), a pharmaceutical acceptable salt thereof, and a solvate thereof,
- wherein R1 and R2 are independently selected from the group consisting of H, —OR, —NO2, —NH2, and a halogen; R in the —OR is one selected from the group consisting of H, (C1-C6)alkyl, (CH2)nPh, SO3 −, and Ar; R3 is one of O and S; R4 is N; X and Y are selected from the group consisting of alkyl, alkenyl, alkynyl, and —OCH2—; R5 is one selected from the group consisting of H, (C1-C15)alkyl, (CH2)nAr and Ar; R6 is one of H and (C1-C6) alkyl and n is an integer from 1˜3.
- Preferably, the two R1 substituents on the benzene ring form the following structure:
- Preferably, R5-R4-R6 fauns a cyclic structure selected from the group consisting of:
- wherein m is an integer from 2-6.
- Preferably, Ar is capable of being substituted by one selected from the group consisting of
- and a heteroaryl group;
- wherein R7, R8, R9 are selected from the group consisting of H, —OH, —OCH3, —NO2, —NH2, —NH3 +, and a halogen; and X— represents an organic base or an inorganic base.
- In accordance with another aspect of the present invention, a pharmaceutical composition for preventing or treating diabetics, comprising a catechol-based derivative described above and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier is provided.
- Preferably, the pharmaceutical composition is used for preventing and treating damages of kidney, brain and heart resulting from an obstruction of a blood vessel (i.e., ischemia).
- In accordance with further aspect of the present invention, a pharmaceutical composition for preventing or treating ischemia, comprising a catechol-based derivative described above and one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.
- Preferably, the pharmaceutical composition is used for preventing and treating damages of kidney, brain and heart resulting from an obstruction of a blood vessel (i.e., ischemia).
- The above aspects and advantages of the present invention will become apparent to those ordinarily skilled in the art after reviewing the following detailed descriptions and accompanying drawings, in which:
-
FIG. 1 shows results from intravenous glucose tolerance test (IGTT) in response to the treatment with compound 370G; -
FIG. 2 shows areas at risk of ischemia after the coronary artery is ligated; and -
FIG. 3 shows the ratios of the cardiac infract size in response to treatment with 370G at different doses. - The present invention will now be described more specifically with reference to the following embodiments. It is to be noted that the following descriptions of preferred embodiments of this invention are presented herein for the purposes of illustration and description only; it is not intended to be exhaustive or to be limited to the precise form disclosed.
- The present invention discloses a series of catechol-based derivatives. The catechol-based derivatives having the formula (I) may be prepared by reacting caffeic acids with alcohols in the presence of an inorganic acid as a catalyst, or alternatively by refluxing the compound containing RNH2 functional groups with the acyl chloride formed by reacting 3(3,4-methylendioxyphenyl)-propenoic acid with dichloromethane (CH2Cl2) and thionyl chloride (SOCl2). An alternative synthesis of the catechol-based derivatives is to mix N,N-dimethylformamide (DMF) and BOP (Benzotrizoly-N-hydroxy trisdimethylamono) phosphonium hexafluororophosphate) in dichloromethane, followed by refluxing the resultant solution with an amino compound, RNH2.
- Reactants for the present invention could be prepared by esterification to convert the original functional group into an ester group. For example, methyl ester may be prepared by refluxing a mixture of p-toluenesulfonic acid (TsOH) and 2,2-dimethoxypropane in methanol. If another ester is desired, it could be prepared by refluxing the mixture of p-toluenesulfonic acid (TsOH) and 2,2-dimethoxypropane in a desire alcohol. The resultant ester may be dissolved in tetrahydrofuran (THF) and reduced with LiAlH4 to the corresponding alcohol. The resultant alcohol may be dissolved in tetrahydrofuran (THF), deprotonated with sodium hydride (NaH), and reacted with an alkyl bromide (RBr) to produce an ether compound.
- Scheme 1 illustrates such a process. Methyl ester is prepared by putting caffeic acid (compound (I) in Scheme 1) in a glass flask, followed by the addition of TsOH, 2,2-dimethoxypropane and the methanol. The resultant solution is heated to reflux to produce methyl ester of caffeic acid. Other esters (other than methyl esters) may be prepared by refluxing the mixture of compound 1 and TsOH in a desired alcohol as a solvent. After the reaction, the solvent is removed and the residue poured into water. The ester is extracted with ethyl acetate. The extract is neutralized and purified with a column chromatography to afford ester derivative (A). Various examples of esters (A) thus prepared are shown in Table 1.
- The ester derivative (A) is dissolved in methanol and hydrogenated in the presence Pd—C as a catalyst to afford a saturated ester. After hydrogenation, the catalyst was removed by filtration and washed with methanol to produce the corresponding saturated ester derivative (B). Various ester (B) thus prepared are shown in Table 2.
- Referring to Scheme 2, under nitrogen atmosphere, a suspension of 3,4-Methylenedioxycinnmamic acid (30) in dry CH2Cl2 is treated with thionyl chloride and heated to reflux. After removal of the solvent in vacuum, an acyl chloride residue is obtained. A solution containing an amine (RNH2) and triethylamine is added to the acyl chloride residue and stirred. After removal of the solvent, the resultant residue is extracted with ethyl acetate. The organic extracts are combined, filtered, and evaporated. The residue is purified by column chromatography to afford derivative (C). Examples of derivative (C) thus prepared are shown in Table 3.
- In a two-neck flask, a derivative (C) is dissolved in CH2Cl2, reacted with BBr3 at approximately −30° C., and then the reaction is terminated with the addition of ice water. The resultant solution is extracted with CH2Cl2. The organic extracts are combined, dried, filtered, and evaporated. The residue is purified with column chromatography to produce derivative (D). Examples of derivative (D) are shown in Table 4.
- Dissolve the type-D derivatives in the methanol, which saturates with hydrogen gases in the presence of Pd—C as a catalyst to give a reactant, followed by filtering the catalyst and washing with methanol to obtain a corresponding type-E derivative. Dissolve the type-E derivatives in a two-neck bottle containing the pyridine, and react the resultant solution with Ac2O at the room temperature for overnight, and then the reaction is terminated with the addition of ice water. The resultant solution is further extracted by CH2Cl2, wherein the organic phase is collected to remove water, to be filtered, to be condensed and perform a column chromatography. Accordingly, type-H derivatives could be obtained, please referring to Table 5.
- Put 10 g of the
compound 30 into a reaction bottle, followed by adding TsOH and 2,2′-dimethyloxypropane dissolved in the methanol solution thereinto. Reflux the resultant solution, and then remove the solvent therefrom, followed by being extracted by the ethyl acetate. Perform a column chromatography of the resultant extract to obtain a product. Dissolve the product in methanol, which saturates with hydrogen gases in the presence of Pd—C as the catalyst. After the reaction, remove the catalyst and wash the methanol to obtain the corresponding compound 56. - Please refer to Scheme 3. Put LiAlH4 into a reaction bottle, and then further add the compound 56 and tetrahydrofuran thereinto, followed by stirring at the room temperature. Reduce the pressure to remove the solvent and then adjust the pH value. Extract the resultant solution by the ethyl ester, wherein the organic phase is condensed to obtain the product 57. The product 57 is stirred in the treatment of NaH and THF for half an hour, followed by adding RBr to react. Reduce the pressure to remove the solvent, followed by being extracted by the ether, wherein the organic phase is collected to obtain type-F derivatives, please referring to Table 7. Dissolve the type-F derivatives in CH2Cl2, and react with BBr3 at −30° C. followed by being extracted by CH2Cl2, collecting the organic phase to remove water, filtering, condensing and performing a column chromatography. Accordingly, type-G derivatives could be obtained, please referring to Table 8.
- Please refer to Scheme 4. Dissolve the caffeic acid in N,N-dimethylformamide and triethylamine, and then react with BOP and CH2Cl2 to obtain the corresponding compound.
- Put a 10 g caffeic acid (1) in a reaction bottle, and add 1 g TsOH and 3 ml 2,2-dimethoxypropane and 10 ml methanol thereinto, followed by refluxing for 6 hours. After the refluxation, remove the solvent and pour the resultant solution into 100 ml water, followed by being extracted by the ethyl acetate for three times, neutralizing with 3% NaHCO3, and finally performing a column chromatography. Therefore, the product, methyl caffeate (the compound 2) is obtained with 98% yield.
- Correspondingly, select the desired alcohol as the replacing group to substitute methanol, so as to synthesize the respective compounds 3-15 of the type-A derivatives.
-
TABLE 1 Type-A derivatives Com- Com- Com- pound R pound R pound R 2 CH3 3 C2H5 4 C3H7 5 C4H9 6 C5H11 7 C6H13 8 C7H15 9 C8H17 10 C9H19 11 C10H21 12 C11H23 13 —CH2Ph 14 —(CH2)2Ph 15 —(CH2)3Ph - Dissolve 200 g methyl cafffeate (2) in 10 ml methanol, which saturates with hydrogen gases in the presence of 20 mg Pd—C, and react for six hours, followed by filtering the catalyst and washing with methanol to obtain the corresponding compound 16 as shown in Table 2.
- Correspondingly, select the respective compounds 3-15 to substitute the original methyl caffeate (2) to react, so as to synthesize the respective compounds 17-29 of the type-B derivatives as shown in Table 2 could be obtained.
-
TABLE 2 Type-B derivatives Com- Com- Com- pound R pound R pound R 16 CH3 17 C2H5 18 C3H7 19 C4H9 20 C5H11 21 C6H13 22 C7H15 23 C8H17 24 C9H19 25 C10H21 26 C11H23 27 —CH2Ph 28 —(CH2)2Ph 29 —(CH2)3Ph - In the presence of nitrogen gases, dissolve a suspension of 10 g 3,4-Methylenedioxycinnmamic acid (30) in 10 ml CH2Cl2, and then add 2 mol thionyl chloride thereinto, followed by refluxing for three hours to remove CH2Cl2 and thionyl chloride therefrom. Add a 10 ml triethylamine solution containing 3 nmol C4H9NH2 under the iced bath and stir the solution for overnight. Remove the triethylamine solution and extract the resulting solution with the 50 ml ethyl ester, wherein the organic phase is collected to remove water by MgSO4, to be filtered, to be condensed and perform a column chromatography. Therefore, the type-C derivatives as shown in Table 3 could be obtained.
- Correspondingly, select the desired amine compound to substitute the C4H9NH2, so as to synthesize the respective compounds 32-38 of the type-C derivatives with 78˜85% yields.
-
TABLE 3 Type-C derivatives Com- Com- Com- pound R pound R pound R 31 C4H9 32 C5H11 33 C6H13 34 C7H15 35 C8H17 36 —CH2Ph 37 —(CH2)2Ph 38 —(CH2)3Ph - In the presence of nitrogen gases, dissolve a 1.0 g N-butyl 3,4-methylenedioxycinnamamide of the type-C derivative into a two-neck bottle containing 10 ml CH2Cl2 Add 1.2 mol BBr3 into the bottle at −30□ to react for four hours. After the reaction is finished, further add 50 ml, 3% NaHCO3 thereinto. Extract the resulting solution by CH2Cl2 three times, and concentrate the organic phase. Remove water from the above organic phase by MgSO4, followed by performing a filtration, a condensation, and a column chromatography. Therefore, the compound 39 as shown in Table 4 could be obtained.
- Correspondingly, select the respective compound 32˜38 to substitute the original compound 31, so as to synthesize the respective compounds 40-46 of the type-D derivatives with 78˜85% yields.
-
TABLE 4 Type-D derivatives Com- Com- pound R pound R 39 C4H9 40 C5H11 41 C6H13 42 C7H15 43 C8H17 44 CH2Ph 45(370G) —(CH2)2Ph 46 —(CH2)3Ph 638A —(CH2)2Ph(OCH3)2 638B —(CH2)2Ph p-Br 638C —(CH2)2Ph p-OH 638D —CH2Ph-p-OCH3 638E —CH2Ph 638F —Ph-p-OCH3 638G —Ph-p-Br 638H Ph p-OH 638I —CH2Ph-m-F - Dissolve a 100 mg caffeic acid in 1 ml N,N-dimethylformamide and 1 mol, 0.08 ml triethylamine in a two-neck bottle, and then add into 1.2 mol, 5 ml CH2Cl2 containing the desired amine compound (RNH2) and 1.2 mol BOP to react for 30 minutes at 0° C., followed by reacting for 2 hours at the room temperature. After the reaction is finished, remove CH2Cl2. The resulting solution is then added into 50 ml water, which is extracted by the ethyl ester. Collect the organic phase, and wash the organic phase with 1 mol HCL, 1 mol NaHCO3 and water, wherein the organic phase is further recollected, followed by removing water therefrom by MgSO4, performing a filtration, a condensation, and a column chromatography. Therefore, the type-D derivatives as shown in Table 5 could be obtained with 65˜85% yield (such as 638A-I). If selecting a ferrulic acid and 2-phenylethanamide to substitute the mentioned compounds, the compound 640 could be obtained.
- Dissolve 200 mg N-alkyl caffeamide in 10 ml methanol, which saturates with hydrogen gases in the presence of 20 mg Pd—C, and react for six hours, followed by filtering the catalyst and washing with methanol to obtain a corresponding compound of the type-E derivatives (the product is 47-54) as shown in Table 5.
-
TABLE 5 Type-E derivatives Com- Com- Com- pound R pound R pound R 47 C4H9 48 C5H11 49 C6H13 50 C7H15 51 C8H17 52 —CH2Ph 53 —(CH2)2Ph 54 —(CH2)3Ph - Put a 10 g the
compound 30 in a reaction bottle, and add 1 g TsOH, 3 ml 2,2-dimethoxypropane and 100 ml methanol thereinto, followed by refluxing for 6 hours. Remove the solvent, and pour the resulting solution into 100 ml water. Then, extract the resultant solution by the ethyl acetate for three times and washed with 3% NaHCO3, followed by performing a column chromatography to obtain the compound A. Dissolve 5 g of the compound A in 20 ml methanol, which saturates with hydrogen gases in the presence of 20 mg Pd—C, and react for six hours, followed by filtering the catalyst and washing with methanol to obtain the corresponding compound 56. - Put LiAlH4 in a reaction bottle, and then add the compound 56 (4 g) and 10 ml tetrahydrofuran thereinto, followed by stirring at the room temperature for the reaction. Add an ether to terminate the reaction. Reduce the pressure to remove the solvent from the resultant solution, and then add 100 ml, 3N H2SO4 thereinto. Extract the resulting solution by the ethyl ester three times, wherein the organic phase is condensed to obtain the product 57.
- At the room temperature, react the compound 57 with 300 g NaH and 10 ml THF by stirring for an hour. Add 3 mol CH3I into the resultant solution to react, followed by reducing the pressure to remove the solvent, pouring into water and successively being extracted by ether. The resultant organic phase is collected to obtain the compound 58.
- According to the preparation of the example 8, the compound 57 serves as a starting material to react respectively with C2H5Br, C3H7Br, and C4H9Br containing an alkyl bromide to substitute CH3I, so as to synthesize the respective compounds 59-61 of the type-F derivatives as shown in Table 7.
-
Type-F derivatives Com- Com- Com- Com- pound R pound R pound R pound R 58 CH3 59 C2H5 60 C3H7 61 C4H9 - According to the preparation of example 4, substitute the type-F derivatives to the type-C derivatives, so as to synthesize the type-G derivatives with 70-75% yield as shown in Table 8.
-
TABLE 8 Type-G derivatives Com- Com- Com- pound R pound R pound R 62 CH3 63 C2H5 64 C3H7 65 C4H9 - In the presence of nitrogen gases, put 50 mg, 0.19 mmol of the compound 370G (45) in a two-neck bottle and dissolve in a 10 ml Pyridine, followed by adding Ac2O therein to react for overnight, and adding the iced water thereinto. Extract the resulting solution by the ethyl ester, and collect the organic phase, remove water therefrom by MgSO4, performing a filtration, and a condensation. Therefore, 50 mg, 0.17 mmol of the pure compound 639B and the mixed compound 639C could be obtained with 88% yields as shown in Table 6.
-
Type-H derivatives Com- pound R R1 R2 639A —(CH2)2Ph CH3 CH3 639B —(CH2)2Ph Ac Ac 639C —(CH2)2Ph Ac{grave over ( )}H 640 —(CH2)2Ph CH3 H - Dissolve a mixture of 370 G (45) and CH3I in acetone and add K2CO3 to reflux, so as to purify the compound 639A.
- According to the preparation of the example 5, react the caffeic acid with the respective N-methyl-2-phenylethanamine, the N-methyl-2-phenylmethamine, the pyrrolidine, the piperidine and the N-methyl-1,4-diazacyclohexane to obtain the respective compound 642A, 642B, 642C and 642D as shown in Table 9.
-
TABLE 9 Type-I derivatives Com- pound R1 R2 R1 + R2 642A CH3 CH2Ph 642C —(CH2)4— 642B CH3 CH2CH2Ph 642D —(CH2)5— - The physical properties of the respective example compounds of the present invention are shown as follows.
- Compound 2: methyl caffeate
- Mp: 160-162° C.
- IR νmax (cm−1): 3485, 3306, 1673, 1631, 1598, 1528, 1275, 1179, 975, 848
- MS m/z (%): 194 (M+, 100), 163 (63), 145 (11), 134 (18)
- 1H-NMR (CDCl3): δ3.78 (3H, s), 5.80, 5.91 (each 1H, br s, —OH), 6.24, 7.56 (each 1H, d, J=15.9 Hz), 6.85 (1H, d, J=8.2 Hz), 6.98 (1H, dd, J=8.2, 2.0 Hz), 7.06 (1H, d, J=2.0 Hz).
- Compound 3
- Mp: 118-120° C.
- IR νmax (cm−1): 3500, 3400, 1652, 1630, 1597, 1279, 1187, 973, 850, 811
- MS m/z (%): 208 (M+, 100), 180 (20), 163 (62), 145 (20), 136 (33)
- 1H-NMR (CDCl3): δ 1.26 (3H, t, J=7.1 Hz), 4.17 (2H, q, J=7.1 Hz), 6.25, 7.53 (each 1H, d, J=15.9 Hz), 6.85 d, J=7.2 Hz), 7.02 (1H, dd, J=7.2, 2.1 Hz), 7.14 (1H, d, J=2.1 Hz), 8.30 (2H, br s, —OH).
- Compound 4
- Mp: 124-126° C.
- IR νmax (cm−1): 3480, 3345, 1684, 1628, 1600, 1528, 1275, 1186, 975, 851, 811
- MS m/z (%): 222 (M+, 100), 180 (57), 163 (78), 145 (13), 138 (22), 136 (21)
- 1H-NMR (CD3COCD3): δ 0.84 (3H, t, J=7.2 Hz), 1.66 (2H, sext, J=7.2 Hz), 4.08 (2H, t, J=7.2 Hz), 6.28, 7.53 (each 1H, d, J=15.9 Hz), 6.86 (1H, d, J=7.1 Hz), 7.03 (1H, dd, J=7.1, 2.0 Hz), 7.15 (1H, d, J=2.0 Hz), 8.28 (2H, br s, —OH).
- Compound 5
- Mp: 106-108° C.
- IR νmax (cm−1): 3479, 3337, 1678, 1632, 1599, 1529, 1276, 1183, 1105, 973, 783, 718
- MS m/z (%): 236 (M+, 83), 180 (100), 163 (73), 145 (12), 136 (25), 134 (23)
- 1H-NMR (CD3COCD3): δ 0.93 (3H, t, J=7.2 Hz), 1.40 (2H, sext, J=7.2 Hz), 1.63 (2H, quin, J=7.2 Hz), 4.13 (2H, t, J=7.2 Hz), 6.26, 7.52 (each 1H, d, J=15.9 Hz), 6.85 (1H, d, J=7.7 Hz), 7.03 (1H, dd, J=7.7, 2.1 Hz), 7.14 (1H, d, J=2.1 Hz).
- Compound 6
- Mp: 140-142° C.
- IR νmax (cm−1): 3486, 3332, 1678, 1632, 1598, 1529. 1276,1181, 974, 851, 783
- MS m/z (%): 250 (M+, 69), 180 (100), 163 (62), 145 (11), 136 (16), 134 (18)
- 1H-NMR (CD3COCD3): δ 0.88 (3H, t, J=6.7 Hz), 1.36 (4H, m), 1.64 (2H, quin, J=7.2 Hz), 4.12 (2H, t, J=7.2 Hz), 6.27, 7.52 (each 1H, d, J=15.9 Hz), 6.85 (1H, d, J=8.2 Hz), 7.04 (1H, dd, J=8.2, 2.2 Hz), 7.15 (1H, d, J=2.2 Hz), 8.30 (2H, br s, —OH).
- Compound 7
- Mp: 115-117° C.
- IRνmax (cm−1): 3483, 3333, 1679, 1632, 1598, 1529, 1275, 1182. 1104, 973, 812
- MS m/z (%): 264 (M+, 43), 180 (100), 163 (57), 145 (13), 136 (20), 134 (19)
- 1H-NMR (CD3COCD3): δ 0.88 (3H, t, J=6.7 Hz), 1.36 (6H, m), 1.64 (2H, quin, J=6.7 Hz), 4.13 (2H, t, J=6.7 Hz), 6.26, 7.52 (each 1H, d, J=15.9 Hz), 6.85 (1H, d, J=8.2 Hz), 7.03 (1H, dd, J=8.2, 2.0 Hz), 7.14 (1H, d, J=2.0 Hz), 8.15 (2H, br s, —OH).
- Compound 8
- Mp: 105-106° C.
- IRνmax (cm−1): 3486, 3337, 1677, 1630, 1598, 1529, 1276, 1181, 1057, 974
- MS m/z (%): 278 (M+, 25), 180 (100), 163 (49), 145 (8), 136 (22), 134 (19), 89 (22)
- 1H-NMR (CD3COCD3): δ 0.88 (3H, t, J=6.7 Hz), 1.36 (8H, m), 1.66 (2H, quin, J=6.7 Hz), 4.13 (2H, t, J=6.7 Hz), 6.27, 7.52 (each 1H, d, J=15.9 Hz), 6.85 (1H, d, J=8.1 Hz), 7.02 (1H, dd, J=8.1, 2.0 Hz), 7.15 (1H, d, J=2.0.Hz), 8.23 (2H, br s, —OH).
- Compound 9
- Mp: 98-100° C.
- IRνmax (cm−1): 3488, 3340, 1675, 1630, 1274, 1181, 972, 812
- MS m/z (%): 292 (M+, 27), 180 (100), 163 (47), 145 (8), 136 (18), 134 (12), 89 (13)
- 1H-NMR (CD3COCD3): δ 0.85 (3H, t, J=6.7 Hz), 1.26 (1014, m), 1.67 (2H, quin J=6.7 Hz), 4.16 (2H, t, J=6.7 Hz), 6.23, 7.54 (each 1H, d, J=15.9 Hz), 6.84 (1H, d, J=8.2 Hz), 6.96 (1H, dd, J=8.2, 2.0 Hz), 7.06 (1H, d, J=2.0 Hz), 8.26 (2H, br s, —OH).
-
Compound 10 - Mp: 87-88° C.
- IRνmax (cm−1): 3476, 3322, 1677, 1629, 1597, 1527, 1274, 1180, 972, 859, 812
- MS m/z (%): 306 (M+, 65), 180 (100), 163 (38), 145 (7), 136 (13), 134 (10), 89 (8)
- 1H-NMR (CDCl3): δ 0.86 (3H, t, J=6.7 Hz), 1.27 (12H, m), 1.66 (214, quin J=6.7 Hz), 4.13 (2H, t, J=6.7 Hz), 6.27, 7.52 (each 1H, d, J=16.0 Hz), 6.85 (1H, d, J=8.1 Hz), 7.03 (1H, dd, J=8.1, 2.0 Hz), 7.14 (1H, d, J=2.0 Hz).
- Compound 11
- Mp: 108-109° C.
- IR νmax (cm−1): 3484, 3326, 1678, 1629, 1597, 1527, 1275, 1181, 972, 859, 812
- MS m/z (%): 320 (M+, 48), 180 (100), 163 (62), 145 (9), 136 (28). 134 (15), 89 (22)
- 1H-NMR (CDCl3): δ 0.85 (3H, t, J=6.7 Hz), 1.24 (14H, m), 1.66 (211, quin, J=6.7 Hz), 4.16 (2H, t, J=6.7 Hz), 5.89, 6.01 (each 1H, br s, —OH), 6.24, 7.55 (each 1H, d, J=16.0 Hz), 6.85 (1.H, d, J=8.2 Hz), 6.98 (1H, dd, J=8.2, 2.0 Hz), 7.03 (1H, d, J=2.0 Hz).
- Compound 12
- Mp: 100-101° C.
- IRνmax (cm−1): 3482, 3326, 1676, 1630, 1596, 1527, 1274, 1180, 972, 849, 810
- MS m/z (%): 334 (M+, 82), 180 (100). 163 (40), 145 (5), 136 (15). 134 (12)
- 1H-NMR (CDCl3): δ 0.85 (3H, t, J=6.6 Hz), 1.24 (16H, m), 167 (2H, quin, J=6.6 Hz), 4.17 (2H, t, J=6.6 Hz), 6.24, 7.56 (each 1H, d, J=15.9 Hz), 6.85 (1H, d, J=8.1 Hz). 6.98 (1H, dd, J=8.1, 2.0 Hz), 7.08 (1H, d, J=2.0 Hz).
- Compound 13; benzyl dihydrocaffeate
- Mp: 150-151° C.
- IRνmax (cm−1): 3461, 3325, 3031. 1627, 1594, 1527, 1274, 1174, 974, 907, 845
- MS m/z (%): 270 (M+, 50), 224 (22), 179 (8), 163 (32), 136 (28), 91 (100), 99 (45)
- 1H-NMR (CD3COCD3): δ 5.20 (2H, s), 6.33, 7.59 (each 1H, d, J=15.9 Hz), 6.86 (1H, d, J=8.1 Hz), 7.05 (1H, dd, J=8.1, 1.7 Hz), 7.17 (1H, d, J=1.7 Hz), 7.21-7.46 (5H, m).
- Compound 14
- Mp: 125-126° C.
- IRνmax (cm−1): 3474, 3326, 1672, 1628, 1593, 1527, 1179, 974, 846, 808
- MS m/z (%): 284 (M+, 24), 180 (100), 163 (45), 135 (17), 104 (32), 91 (22), 89 (25)
- 1H-NMR (CDCl3): δ 2.99, 4.39 (each 2H, t, J=6.8 Hz), 6.20, 7.54 (each 1H, d, J=15.8 Hz), 6.85 (1H, d, J=8.0 Hz), 6.95 (1H, d, J=8.0, 2.0 Hz), 7.06 (1H, d, J=2.0 Hz), 7.13-7.35 (5H, m).
- Compound 15
- Mp: 102-103° C.
- IRνmax (cm−1): 3482, 3327, 1671, 1629, 1597, 1179, 973. 809, 696
- MS m/z (%): 298 (M+, 18), 180 (100), 163 (19), 135 (8), 118 (30), 117 (30), 91 (24)
- 1H-NMR (CDCl3): δ 2.01 (2H, quin, J=6.8 Hz), 2.72, 4.20 (each 2H, t, J=6.8 Hz), 6.25, 7.55 (each 1H, d, J=15.9 Hz), 6.85 (1H, d, J=8.2 Hz), 6.98 (1H, d, J=8.2, 1.8 Hz), 7.08 (1H, d, J=1.8 Hz), 7.10-7.30 (5H, s).
- Compound 16
- Mp: amorphous
- IRνmax (cm−1): 3382, 1706, 1601, 1515, 1.279, 1111, 815
- MS m/z (%): 195 (M+−1, 45), 136 (54), 123 (100), 107 (10), 91 (18), 77 (22)
- 1H-NMR (CD3COCD3): δ 2.51, 2.74 (each 2H, t, J=7.2 Hz), 3.58 (3H, s), 6.53 (1H, dd, J=7.8, 2.1 Hz), 6.69 (1H, d, J=2.1 Hz), 6.71 (1H, d, J=7.8 hz).
- Compound 17
- Mp: amorphous
- IRνmax (cm−1): 3373, 1705, 1601, 1515, 1281, 1193, 1110, 954, 962, 811
- MS m/z (%): 210 (M+, 77), 196 (8), 181 (9), 165 (23), 136 (60), 123 (100), 91 (18)
- 1H-NMR (CD3COCD3): δ 1.17 (3H, t, J=7.1 Hz), 2.50, 2.74 (each. 2H, t, J=7.8 Hz), 4.05 (2H, q, J=7.1 Hz), 6.53 (1H, dd, J=7.9, 1.8 Hz), 6.70 (1H, d, J=1.8 Hz), 6.71 (1H, d, J=7.1 Hz), 7.69 (2H, br s, —OH).
- Compound 18
- Mp: amorphous
- IRνmax (cm−1): 3382, 1704, 1601, 1515, 1256, 1110, 1032, 952, 865, 812
- MS m/z (%): 224 (M+, 40), 195 (12), 181 (20), 164 (21), 152 (14), 139 (42), 136 (82), 123 (100), 110 (16), 91 (31), 77 (25)
- 1H-NMR (CD3COCD3): δ 0.87 (3H, t, J=6.8 Hz), 1.58 (2H, sext, J=6.8 Hz), 2.51, 2.74 (each 2H, t, J=7.3 Hz), 3.96 (2H, t, J=6.8 Hz), 6.53 (1H, dd, J=8.2, 1.9 Hz), 6.70 (1H, d, J=1.9 Hz), 6.71 (1H, d, J=8.2 Hz), 7.70 (2H, br s, —OH).
- Compound 19
- Mp: amorphous
- IRνmax (cm−1): 3382, 1701, 1601, 1515, 1441, 1279, 1192, 1110, 1023, 865, 811
- MS m/z (%): 238 (M+, 82), 180 (18), 164 (25), 139 (29), 136 (61), 123 (100), 91 (13)
- 1H-NMR (CD3COCD3): δ 0.88 (3H, t, J=6.7 Hz), 1.31 (2H, sext, J=6.7 Hz), 1.55 (2H, quin, J=6.7 Hz), 2.51, 2.74 (each 2H, t, J=7.6 Hz), 4.01 (2H, t, J=6.7 Hz), 6.53 (1H, dd, J=8.1, 1.8 Hz), 6.69 (1H, dd, J=1.8 Hz), 6.70 (1H, dd, J=8.1 Hz), 7.65 (2H, br s, —OH).
-
Compound 20 - Mp: 68-70° C.
- IRνmax (cm−1): 3390, 1702, 1602, 1515, 1439, 1357, 1281, 1110, 811
- MS m/z (%): 252 (M+, 52), 195 (2), 181 (28), 164 (10), 139 (40), 136 (78), 123 (100), 91 (21)
- 1H-NMR (CDCl3): δ 0.87 (3H, t, J=6.8 Hz), 1.28 (4H, m), 1.57 (2H, quin, J=6.8 Hz), 2.51, 2.74 (each 2H, t, J=7.2 Hz), 4.01 (2H, t, J=6.8 Hz), 6.53 (1H, dd, J=8.0, 2.2 Hz), 6.70 (1H, d, J=2.2 Hz), 6.71 (1H, dd, J=8.0 Hz), 7.66 (2H, br s, —OH).
- Compound 21
- Mp: 64-66° C.
- IRνmax (cm−1): 3386, 1702, 1602, 1515, 1439, 1357, 1281, 1110, 811
- MS m/z (%): 266 (M+, 42), 195 (3), 181 (36), 164 (8), 139 (42), 136 (75), 123 (100), 91(17), 42 (42)
- 1H-NMR (CD3COCD3): δ 0.87 (3H, t, J=6.7 Hz), 1.28 (6H, m), 1.57 (2H, quin, J=6.7 Hz), 2.51, 2.74 (each 2H, t, J=7.3 Hz), 4.01 (2H, t, J=6.7 Hz), 6.53 (1H, dd, J=8.1, 1.6 Hz), 6.69 (1H, d, J=1.6 Hz), 6.70 (1H, dd, J=8.1 Hz), 7.60 (2H, br s, —OH).
- Compound 22
- Mp: 60-62° C.
- IRνmax (cm−1): 3388, 1704, 1598, 1511, 1279, 1110, 810
- MS m/z (%): 280 (M+, 27), 182 (37), 139 (32), 136 (55), 123 (100), 91 (13), 77 (11), 57 (41), 55 (31)
- 1H-NMR (CDCl3): δ 0.85 (3H, t, J=6.7 Hz), 1.24 (8H, br s), 1.55 (2H, quin, J=6.7 Hz), 2.55, 2.79 (each 2H, t, J=7.4 Hz), 4.03 (2H, t, J=6.7 Hz), 6.12, 6.30 (each 1H, br s, —OH), 6.57 (1H, dd, J=8.2, 1.5 Hz), 6.67 (1H, d, J=1.5 Hz), 6.73 (1H, d, J=8.2 Hz).
- Compound 23
- Mp: 52-54° C.
- IRνmax (cm−1): 3395, 1701, 1600, 1512, 1279, 1190, 1026, 864, 811, 784
- MS m/z (%): 294 (M+, 31), 182 (43), 136 (53), 123 (100), 91 (11), 55 (22)
- 1H-NMR (CDCl3): δ 0.85 (3H, t, J=6.8 Hz), 1.24 (10H, br s), 1.55 (2H, quin, J=6.8 Hz), 2.55, 2.80 (each 2H, t, J=7.2 Hz), 4.03 (2H, t, J=6.8 Hz), 6.57 (1H, dd, J=8.0, 1.9 Hz), 6.68 (1H, d, J=1.9 Hz), 6.73 (1H, d, J=8.0 Hz).
- Compound 24
- Mp: 43-45° C.
- IRνmax (cm−1): 3400, 1703, 1601, 1515, 1279, 1192, 1110, 1051, 865, 812, 722
- MS m/z (%): 308 (M+, 47), 181 (50), 164 (7), 139 (36), 138 (82), 125 (100), 91 (20), 57 (19), 55 (30), 43 (47)
- 1H-NMR (CD3COCD3): δ 0.86 (3H, t, J=6.8 Hz), 1.28 (12H, br s), 1.55 (2H, quin, J=6.8 Hz), 2.51, 2.74 (each 2H, t, J=7.4 Hz). 4.01 (2H, t, J=6.8 Hz), 6.53 (1H, dd, J=8.0, 2.0 Hz), 6.69 (1H, d, J=2.0 Hz), 6.71 (1H, d, J=8.0 Hz).
- Compound 25
- Mp: 53-55° C.
- IRνmax (cm−1): 3410, 1702, 1600, 1512, 1280, 1191, 1110, 1039, 865, 810, 721
- MS m/z (%): 322 (M+, 52), 182 (90), 139 (43), 137 (37), 136 (100), 123 (95), 91 (15), 60 (32), 55 (38)
- 1H-NMR (CDCl3): δ 0.85 (3H, t, J=6.7 Hz), 1.24 (14H, br s), 1.55 (2H, quin, J=6.7 Hz), 2.50, 2.73 (each 2H, t, J=7.2 Hz), 4.03 (2H, t, J=6.7 Hz), 6.56 (1H, dd, J=8.1, 2.0 Hz), 6.68 (1H, d, J=1.9 Hz), 6.73 (1H, d, J=8.1 Hz).
- Compound 26
- Mp: 54-56° C.
- IRνmax (cm−1): 3390, 1721, 1598, 1507, 1274, 1189, 1048, 870, 811, 722
- MS m/z (%): 336 (M+, 72), 182 (73), 139 (38), 136 (90), 123 (100), 91 (10), 57 (29), 55 (28)
- 1H-NMR (CDCl3): δ 0.85 (3H, t, J=6.7 Hz), 1.23 (16H, br s), 1.57 (2H, quin, J=6.7 Hz), 2.55, 2.80 (each 2H, t, J=7.1 Hz), 4.03 (2H, t, J=6.7 Hz), 6.64 (1H, dd, J=8.0, 1.8 Hz), 6.68 (1H, d, J=1.8 Hz), 6.73 (1H, d, J=8.0 Hz).
- Compound 27
- Mp: amorphous
- IRνmax (cm−1): 3387, 1702, 1599, 1512, 1278, 1109, 1025, 813, 748, 697
- MS m/z (%): 272 (M+, 31), 181 (63), 139 (100), 123 (40), 91 (72), 90 (78), 77 (32), 65 (34), 55 (15), 51 (23)
- 1H-NMR (CDCl3): δ 2.61, 2.81 (each 2H, J=7.1 Hz), 5.08 (2H, s), 6.56 (1H, dd, J=8.0, 1.9 Hz), 6.64 (1H, d, J=1.9 Hz), 6.72 (1H, d, J=8.0 Hz), 7.24-7.38 (5H, m).
- Compound 28
- Mp: amorphous
- IRνmax (cm−1): 3403, 1702, 1598, 1511, 1278, 1110, 1050, 813, 748, 699
- MS m/z (%): 286 (M+, 22), 182 (34), 136 (30), 123 (83), 105 (100), 104 (27), 91 (36), 90 (37), 77 (41), 65 (31), 51 (22)
- 1H-NMR (CDCl3): δ 2.54, 2.77 (each 2H, t, J=7.3 Hz), 2.88, 4.25 (each 2H, t, J=7.0 Hz), 6.54 (1H, dd, J=8.2, 1.9 Hz), 6.61 (1H, d, J=1.9 Hz), 6.72 (1H, d, J=8.2 Hz), 7.15-7.38 (5H, m).
- Compound 29
- Mp: amorphous
- IRνmax (cm−1): 3404, 1701, 1598, 1512, 1279, 1190, 1109, 1027, 912, 865, 811, 746
- MS m/z (%): 300 (M+, 92), 182 (100), 165 (11), 139 (28), 136 (48), 123 (93), 118 (53), 91 (80), 77 (25), 65 (22), 55 (15)
- 1H-NMR (CDCl3): δ 1.91 (2H, quin, J=6.7 Hz), 2.58, 2.81 (each 2H, t, J=6.7 Hz), 2.62, 4.07 (each 2H, t, J=6.6 Hz), 6.65 (1H, dd, J=8.0. 1.9 Hz), 6.70 (1H, d, J=1.9 Hz), 6.74 (1H, d, J=8.0 Hz), 7.08-7.31 (5H, m).
- Compound 31
- Mp: 82-83° C.
- IRνmax (cm−1): 3279, 3080, 1648, 1607, 1541, 1353, 1246, 1099, 1037, 977, 930, 807
- MS m/z (%): 247 (M+, 82), 190 (53), 175 (100), 145 (61), 135 (41), 117 (30), 89 (50), 63 (16)
- 1H-NMR (CDCl3): δ 0.89 (3H, t, J=7.1 Hz), 1.32 (2H, sext, J=7.1 Hz), 1.50, (2H, quin, J=7.1 Hz), 3.34 (2H, q, J=7.1 Hz), 5.90 (1H, br s, —NH), 5.94 (2H, s,), 6.22, 7.48 (each 1H, d, J=15.5 Hz), 6.73 (1H, d, J=8.0 Hz), 6.91 (1H, dd, J=8.0, 1.6 Hz), 6.94 (1H, d, J=1.6 Hz).
- Compound 32
- Mp: 95-96° C.
- IRνmax (cm−1): 3276, 3070, 1650, 1604, 1543, 1494, 1352, 1325, 1246, 1110, 1037, 928, 850, 808
- MS m/z (%): 261 (M+, 81), 261 (81), 190 (46), 175 (100), 145 (50), 135 (38), 117 (27), 89 (48), 63 (13)
- 1H-NMR (CDCl3): δ 0.74 (3H, t, J=6.8 Hz), 1.17 (4H, m), 1.49 (2H, quin, J=6.8 Hz), 3.24 (2H, q, J=6.8 Hz), 5.80 (2H, s), 6.38, 7.39 (each 1H, d, J=15.5 Hz), 6.57 (1H, d, J=8.0 Hz), 6.79 (1H, dd, J=8.0, 1.4 Hz), 6.85 (1H, d, J=1.4 Hz), 7.23 (1H, t, J=6.8 Hz, —NH).
- Compound 33
- Mp: 75-76° C.
- IRνmax (cm−1): 3281, 3072, 1648, 1605, 1542, 1325, 1246, 1100, 1037, 976, 928
- MS m/z (%): 275 (M+, 52), 190 (43), 175 (100), 145 (46), 135 (29), 117 (25), 100 (8), 89 (47), 63 (13)
- 1H-NMR (CDCl3): δ 0.76 (3H, t, J=6.7 Hz), 1.23 (6H, m), 1.49 (2H, quin, J=6.7 Hz), 3.28 (2H, q, J=6.7 Hz), 5.84 (2H, s), 6.36, 7.43 (each 1H, d, J=15.5 Hz), 6.61 (1H, d, J=8.0 Hz), 6.82 (1H, dd, J=8.0, 1.6 Hz), 6.86 (1H, d, J=1.6 Hz), 7.03 (1H, t, J=6.7 Hz, —NH).
- Compound 34
- Mp: 108-109° C.
- IRνmax (cm−1): 3288, 3069, 1641, 1604, 1530, 1254, 1100, 1041, 966, 929, 854, 815, 724
- MS m/z (%): 289 (M+, 28), 190 (37), 175 (100), 145 (40), 135 (23), 117 (22), 89 (41), 63 (13), 55 (11)
- 1H-NMR (CDCl3): δ 0.84 (3H, t, J=6.6 Hz), 1.25 (8H, m), 1.51 (2H, quin, J=6.6 Hz), 3.32 (2H, q, J=6.6 Hz), 5.79 (1H, br s, —NH), 5.95 (2H, s), 6.21, 7.50 (each 1H, d, J=15.5 Hz), 6.75 (1H, d, J=7.9 Hz), 6.94 (1H, dd, J=7.9, 1.6 Hz), 6.96 (1H, d, J=1.6 Hz).
- Compound 35
- Mp: 69-70° C.
- IRνmax (cm−1): 3294, 3072, 1642, 1604, 1541, 1352, 1325, 1244, 1098, 1138, 975, 931, 850, 807
- MS m/z (%): 303 (M+, 28), 190 (35), 175 (100), 145 (40), 135 (23), 117 (22), 89 (34), 63 (13), 55 (9)
- 1H-NMR (CDCl3): δ 0.80 (3H, t, J=6.4 Hz), 1.25 (10H, m), 1.52 (2H, quin, J=6.4 Hz), 3.30 (2H, q, J=6.4 Hz), 5.88 (2H, s), 6.33, 7.44 (each 1H, d, J=15.6 Hz), 6.65 (1H, d, J=8.0 Hz), 6.85 (1H, dd, J=8.0, 1.6 Hz), 6.88 (1H, d, J=1.6 Hz).
- Compound 36
- Mp: 124-125° C.
- IRνmax (cm−1): 3408, 3070, 1648, 1604, 1350, 1245, 1035, 698
- MS m/z (%): 281 (M+, 50), 190 (47), 175 (100), 145 (45), 135 (23), 91 (97)
- 1H-NMR (CDCl3): δ 4.51 (2H, d, J=5.7 Hz), 5.94 (2H, s), 6.24, 7.53 (each 1H, d, J=15.5 Hz), 6.74 (1H, d, J=8.0 Hz), 6.92 (1H, dd, J=8.0, 19 Hz), 6.94 (1H, d, J=1.9 Hz), 7.16-7.37 (5H, m).
- Compound 37
- Mp: 123-125° C.
- IRνmax (cm−1): 3288, 3071, 1650, 1610, 1604, 1575, 1548, 1500, 1358, 1250, 1039, 970, 930, 813
- MS m/z (%): 295 (M+, 35), 190 (42), 175 (100), 174 (28), 145 (27), 117 (11), 89 (18), 68 (8)
- 1H-NMR (CDCl3): δ 2.84 (2H, d, J=7.2 Hz), 3.58 (2H, q, J=7.2 Hz), 5.85 (2H, s), 6.32, 7.49 (each 1H, d, J=15.5 Hz), 6.66 (1H, d, J=7.9 Hz), 6.86 (1H, dd, J=7.9, 1.5 Hz), 6.90 (1H, d, J=1.5 Hz), 7.17-7.38 (5H, m).
- Compound 38
- Mp: 126-127° C.
- IRνmax (cm−1): 3295, 1641, 1613, 1543, 1494, 1352, 1320, 1246, 1036, 966, 857, 813, 751
- MS m/z (%): 309 (M+, 58), 240 (34), 190 (16), 145 (47), 135 (25), 117 (26), 89 (33), 63 (10).
- 1H-NMR (CDCl3): δ 1.84 (2H, quin, J=7.4 Hz), 2.66 (2H, t, J=7.4 Hz), 3.32 (2H, q, J=7.4 Hz), 6.02 (2H, s), 6.53, 7.44 (each 1H, d, J=15.6 Hz), 6.84 (1H, d, J=7.9 Hz), 7.03 (1H, dd, J=7.9, 1.6 Hz), 7.09 (1H, d, J=1.6 Hz), 7.20-7.40 (5H, m).
- Compound 39
- Mp: 103-104° C.
- IRνmax (cm−1): 3339, 1641, 1558, 1362, 1278, 1117, 976, 848, 809
- MS m/z (%): 235 (M+, 60), 178 (41); 163 (100), 145 (20), 135 (22), 117 (20), 89 (32), 55 (36)
- 1H-NMR (CD3COCD3): δ 0.88 (3H, t, J=7.2 Hz), 1.33 (2H, sext, J=7.2 Hz), 1.49 (2H, quin, J=7.2 Hz), 3.31 (2H, q, J=7.2 Hz), 6.46, 7.43 (each 1H, d, J=15.5 Hz), 6.82 (1H, d, J=8.1 Hz), 6.91 (1H, dd, J=8.1, 1.9.Hz), 7.09 (1H, d. J=1.9 Hz).
-
Compound 40 - Mp: 124-125° C.
- IR νmax (cm−1): 3407, 1642, 1587, 1363, 1277, 1111, 974, 813
- MS m/z (%): 249 (M+, 64), 178 (33), 163 (100), 162 (43), 145 (20), 135 (33), 117 (20), 89 (29), 86 (20), 77 (13)
- 1H-NMR (CD3COCD3): δ 0.84 (3H, t, J=7.0 Hz), 1.29 (4H, m), 1.53 (2H, quin, J=7.0 Hz), 3.31 (2H, q, J=7.0 Hz), 6.48, 7.45 (each 1H, d, J=15.6 Hz), 6.83 (1H, d, J=8.2 Hz), 6.92 (1H, dd, J=8.2, 1.8 Hz), 7.10 (1H, d, J=1.8 Hz).
- Compound 41
- Mp: 106-108° C.
- IR νmax (cm−1): 3219, 1648, 1588, 1362, 1278, 1113, 976, 852, 811, 726
- MS m/z (%): 263 (M+, 32), 178 (45), 164 (75), 163 (100), 162 (43), 145 (12), 135 (23), 117 (16), 100 (26), 89 (27), 84 (15), 77 (13)
- 1H-NMR (CD3COCD3): δ 0.83 (3H, t, J=6.8 Hz), 1.26 (6H, m), 1.54 (2H, quin, J=6.8 Hz), 3.30 (2H, q, J=6.8 Hz), 6.57, 7.51 (each 1H, d, J=15.6 Hz), 6.84 (1H, d, J=8.1 Hz), 6.92 (1H, dd, J=8.1. 1.6 Hz), 7.12 (1H, d, J=1.6 Hz).
- Compound 42
- Mp: 126-127° C.
- IR νmax (cm−1): 3347, 1642, 1588, 1545, 1510, 1363, 1266, 1112, 975, 809
- MS m/z (%): 277 (M+, 42), 192 (10), 178 (32), 163 (100), 145 (12), 135 (20), 114 (14), 98 (8)
- 1H-NMR (CD3COCD3): δ 0.82 (3H, t, J=6.6 Hz), 1.20 (8H, m), 1.52 (2H, quin, J=6.6 Hz), 3.32 (2H, q, J=6.6 Hz), 6.51, 7.48 (each 1H, d, J=15.6 Hz), 6.83 (1H, d, J=8.1 Hz), 6.92 (1H, dd, J=8.1, 1.5 Hz), 7.11 (1H, d, J=1.5 Hz).
- Compound 43
- Mp: 111-112° C.
- IR νmax (cm−1): 3286, 1642, 1588, 1520, 1363, 1277, 1112, 975, 811
- MS m/z (%): 291 (M+, 18), 220 (8), 193 (11), 178 (31), 163 (100), 145 (8), 135 (13), 128 (22), 117 (11), 98 (8), 89 (19), 84 (12)
- 1H-NMR (CD3COCD3): δ 0.84 (3H, t, J=6.6 Hz), 1.24 (10H, m), 1.52 (2H, quin, J=6.6 Hz), 3.30 (2H, q, J=6.6 Hz), 6.47, 7.42 (each 1H, d, J=15.6 Hz), 6.82 (1H, d, J=8.2 Hz), 6.90 (1H, dd, J=8.2, 1.8 Hz), 7.09 (1H, d, J=1.8 Hz).
- Compound 44
- Mp: 165-167° C.
- IR νmax (cm−1): 3263, 1641, 1591, 1518, 1354, 1279, 1113, 1080, 1029, 975, 850, 813, 738
- MS m/z (%): 269 (M+, 18), 164 (27), 163 (1001), 136 (12), 106 (100), 91 (28), 89 (15)
- 1H-NMR (CD3COCD33): δ 4.50 (2H, d, J=5.8 Hz), 6.56, 7.50 (each 1H, d, J=15.6 Hz), 6.83 (1H, d, J=8.0 Hz), 6.91 (1H, dd, J=8.0 Hz, 1.6 Hz), 7.11 (1H, d, J=1.6 Hz), 7.21-7.36 (5H, m).
- Compound 45
- Mp: 147-149° C.
- IR νmax (cm−1): 3288, 1642, 1591, 1523, 1361, 1279, 1036, 975, 849, 812, 749, 700
- MS m/z (%): 283 (M+, 17), 178 (22), 163 (100), 145 (9), 135 (7), 117 (8), 91 (13)
- 1H-NMR (CD3COCD3): δ 2.84 (2H, t, J=6.8 Hz), 3.53 (2H, q, J=6.8 Hz), 6.43, 7.43 (each 1H, d, J=15.2 Hz), 6.83 (1H, d, J=8.1 Hz), 6.92 (1H, dd, J=8.1, 1.8 Hz), 7.07 (1H, d, J=1.8 Hz), 7.15-7.30 (5H, m)
- Compound 46
- Mp: 125-127° C.
- IR νmax (cm−1): 3326, 1642, 1587, 1362, 1279, 1112, 976, 851, 813, 748
- MS m/z (%): 297 (M+, 46), 192 (38), 175 (30), 164 (100), 163 (84), 145 (18), 135 (26), 117 (35), 91 (50), 84 (48), 69 (30)
- 1H-NMR (CD3COCD3): δ 1.86 (2H, quin, J=7.4 Hz), 2.63 (2H, t, J=7.4 Hz), 3.39 (2H, m), 6.59, 7.56 (each 1H, d, J=15.6 Hz), 6.89 (1H, d, J=8.1 Hz), 6.94 (1H, dd, J=8.1, 1.6 Hz), 7.08-7.28 (5H, m).
- Compound 47
- Mp: 81-82° C.
- IR νmax (cm−1): 3291, 3045, 1640, 1530, 1361, 1279, 1111, 810, 783
- MS m/z (%): 237 (M+, 79), 165(12), 136(79), 123(100), 115(27), 91(23), 74 (82)
- 1H-NMR (CDCl3): δ 0.84 (3H, t, J=7.1 Hz), 1.26 (2H, sex, J=7.1 Hz), 1.40 (2H, quin, J=7.1 Hz), 2.42, 2.75 (each 2H, t, J=7.3 Hz), 3.15 (2H, q, J=7.1 Hz), 6.50 (1H, br d, J=7.9 Hz), 6.71 (2H, m), 7.42 (2H, br s. —NH).
- Compound 48
- Mp: 99-101° C.
- IR νmax (cm−1): 3319, 3054, 1630, 1535, 1361, 1279, 1147, 1111, 810
- MS m/z (%): 251 (M+, 69), 165(12), 136(64), 123(100), 114(15), 88 (47)
- 1H-NMR (CD3COCD3): δ 0.85 (311, t, J=6.8 Hz), 1.22 (4H, m), 1.42 (2H, quin, J=6.8 Hz), 2.36, 2.74 (each 2H, t, J=7.2 Hz), 3.14 (2H, q, J=6.8 Hz), 6.50 (111, dd, J=8.2, 1.9 Hz), 6.68 (111, d, J=1.9 Hz), 6.69 (1H, d, J=8.2 Hz), 7.10 (1H, brs. —NH).
- Compound 49
- Mp: 83-85° C.
- IR νmax (cm−1): 3289, 3051, 1630, 1545, 1361, 1278, 1194, 1111, 810
- MS m/z (%): 265 (M+, 78), 165(16), 136(63), 123(100), 102(47), 91 (18)
- 1H-NMR (CD3COCD3): δ 0.84 (3H, t. J=7.0 Hz), 1.24 (6H, brs), 1.41 (2H, quin, J=7.0 Hz), 2.41, 2.75 (each 2H, t, J=7.3 Hz), 3.14 (214, q, J=7.0 Hz), 6.51 (1H, dd, J=8.0, 2.0 Hz), 6.70 (114, d, J=8.0 Hz), 6.71 (1H, d, J=2.0 Hz), 7.40 (1H, brs, —NH).
-
Compound 50 - Mp: 114-116° C.
- IR νmax (cm−1): 3307, 3044, 1644, 1530, 1279, 1192, 1110, 810
- MS m/z (%): 279 (M+, 100), 165(15), 136(72), 123(100), 116(48), 91 (15)
- 1H-NMR (CD3COCD3): δ 0.85 (3H, t, J=6.7 Hz), 1.25 (814, br s), 1.42 (2H, quin, J=6.4 Hz), 2.36, 2.74 (each 2H, t, J=7.5 Hz), 3.14 (2H, q, J=6.4 Hz), 6.49 (114, dd, J=7.9, 1.9 Hz), 6.69 (1H, d, J=1.9 Hz), 6.69 (1H, d, J=7.9 Hz), 7.10 (111, br s, —NH), 7.80 (211, brs, —OH).
- Compound 51
- Mp: 80-82° C.
- IR νmax (cm−1): 3286, 3041, 1635, 1540, 1361, 1279, 1110, 809
- MS m/z (%): 293 (M+, 100), 165(9), 136(40), 130(25), 123 (35)
- 1H-NMR (CD3COCD3): δ 0.85 (314, t, J=6.9 Hz), 1.25 (10H, br s), 1.42 (214, quin, J=6.9 Hz), 6.50 (1H, dd, J=8.1, 1.9 Hz), 6.69 (111, d, J=8.1 Hz), 6.70 (111, d, J=1.9 Hz), 7.18 (1H, br s, —NH), 7.85, 7.97 (each 1H, br s, —OH).
- Compound 52
- Mp: 149-151° C.
- IR νmax (cm−1): 3307, 3050, 1633, 1517, 1279, 1111, 813, 699
- MS m/z (%): 271 (M+, 83), 148(51), 136(23), 123 (31). 106(31), 91 (100)
- 1H-NMR (CDCl3): δ 2.50, 2.80 (each 2H, t, J=7.4 Hz), 4.37 (2H, d, J=6.0 Hz), 6.53 (1H, dd, J=8.0, 1.9 Hz), 6.72 (1H, d, J=8.0 Hz), 6.73 (1H, d, J=1.9 Hz), 7.22 (5H, m), 7.67 (111, br s, —NH), 7.80 (2H, br s, —OH).
- Compound 53
- Mp: 129-131° C.
- IR νmax (cm−1): 3287, 3042, 1633, 1523, 1355, 1195, 1111, 812
- MS m/z (%): 285 (M+, 8), 165(21), 136 (27). 123(100), 91 (30)
- 1H-NMR (CDCl3): δ 2.41, 2.73 (each 2H, t, J=6.9 Hz), 2.76 (2H, t, J=6.9 Hz), 3.40 (2H, q, J=6.9 Hz), 6.52 (111, dd, J=8.0. 1.8 Hz), 6.74 (1H, d, J=1.8 Hz), 6.74 (1H, d, J=8.0 Hz), 7.20 (5H, m), 7.36 (1H, br s, —NH), 8.03 (2H, br s, —OH).
- Compound 54
- Mp: 127-1291° C.
- IR νmax (cm−1): 3351, 3035, 1633, 1523, 1280, 1111, 750, 700
- MS m/z (%): 299 (M+, 77), 195(40), 136(81), 123(100), 118(30), 91(73), 77(24), 73 (42)
- 1H-NMR (CD3COCD3): δ 1.78 (2H, quin, J=7.6 Hz), 2.41, 2.76 (each 2H, t, J=7.4 Hz), 2.57 (2H, t, J=7.6 Hz), 3.19 (2H, q, J=7.6 Hz), 6.52 (1H, dd, J=8.0, 1.9 Hz), 6.71 (1H, d, J=8.0 Hz), 6.72 (1H, d, J=1.9 Hz), 7.20 (5H, m), 7.28 (1H, br s, —NH), 7.90 (2H, br s, —OH).
- Compound 55
- Mp: 51-52° C.
- IR νmax (cm−1): 3030, 1703, 1620, 1595, 1490, 1303, 1264, 1104, 1006, 863
- MS m/z (%): 206 (M+, 100), 175(56), 145(21), 117 (9)
- 1H-NMR (CDCl3): δ 3.77 (3H, s), 5.98 (211, s), 6.24, 7.58 (each 1H, d, =15.9 Hz), 6.80 (1H, d, J=8.0 Hz), 6.97 (1H, dd, J=8.0, 2.0 Hz), 7.00 (1H, d, J=2.0 Hz).
- Compound 56
- Mp: liquid
- 1H-NMR (CDCl3): δ 2.54, 2.82 (each 2H, t, J=7.3 Hz), 3.62 (3H, s), 5.87 (2H, s), 6.63 (1H, dd, J=7.9, 1.6 Hz), 6.65 (1H, d, J=1.6 Hz), 6.69 (1H, d, J=7.9 Hz).
- Compound 57
- Mp: liquid
- 1H-NMR (CDCl3): δ 1.79 (214, m), 2.57 (2H, t, J=7.7 Hz), 3.60 (each 2H, t, J=6.5 Hz), 4.35 (1H, br s, —OH), 5.86 (2H, s), 6.59 (1H, dd, J=7.9, 1.5 Hz), 6.65 (1H, d, J=1.5 Hz), 6.69 (1H, d, J=7.9 Hz).
- Compound 58
- Mp: liquid
- IR νmax (cm−1): 3043, 1602, 1500, 1482, 1242, 1114, 1038, 929, 808
- MS m/z (%): 194 (M+, 65), 162 (44). 136(92), 135(100), 104(27), 77 (37)
- 1H-NMR (CDCl3): δ 1.81 (211, m), 2.58 (2H, t, J=7.6 Hz), 3.31 (3H, s), 3.50 (2H, t, J=6.4 Hz), 5.89 (2H, s), 6.61 (1H, dd, J=7.8, 1.4 Hz), 6.67 (1H, d, J=1.5 Hz), 6.71 (1H, d, J=7.8 Hz).
- Compound 59
- Mp: liquid
- IR νmax (cm−1): 3038, 1602, 1501, 1482, 1242, 1107, 1038, 808
- MS m/z (%): 208 (M+, 53), 162(100), 136(82), 135(95), 104(44), 77 (42)
- 1H-NMR (CDCl3) δ 1.19 (3H, t, J=7.5 Hz), 1.83 (2H, m), 2.59 (2H, t, =7.6 Hz), 3.38 (2H, q, J=7.5 Hz), 3.49 (2H, d, J=7.1 Hz), 5.88 (2H, s), 6.60 (1H, dd, J=7.8, 1.6 Hz), 6.67 (1H, d, J=1.6 Hz), 6.70 (1H, d, J=7.8 Hz).
-
Compound 60 - Mp: liquid
- IRνmax (cm−1): 3051, 1602, 1500, 1481, 1242, 1185, 1113, 1038, 938
- MS m/z (%): 222 (M+, 37), 162(100), 136(71), 135(71), 104(31), 77 (38)
- 1H-NMR (CDCl3): δ 0.92 (3H, t, J=7.3 Hz), 1.59 (211, sex, J=7.3 Hz), 1.83 (2H, m), 2.60 (2H, d, J=7.6 Hz), 3.34 (211, t, J=7.3 Hz), 3.38 (211, t, J=6.6 Hz), 5.87 (2H, s), 6.61 (1H, dd, J=7.8, 1.5 Hz), 6.67 (1H, d, J=1.5 Hz), 6.70 (1H, d, J=7.8 Hz).
- Compound 61
- Mp: liquid
- IR νmax (cm−1): 3050, 1602, 1500, 1482, 1242, 1110, 930, 808
- MS m/z (%): 236 (M+, 27), 162(100), 136(60), 135 (48). 104(27), 77 (31)
- 1H-NMR (CDCl3): δ 0.90 (3H, t, J=7.1 Hz), 1.36 (2H, m), 1.54 (2H, m), 1.83 (2H, m), 2.59 (2H, t, J=7.6 Hz), 3.37 (2H, t, J=7.1 Hz), 3.38 (2H, t, J=6.8 Hz), 5.89 (2H, s), 6.64 (1H, dd, J=7.9, 1.5 Hz), 6.67 (1H, d, J=1.5 Hz), 6.70 (1H, d, J=7.9 Hz).
- Compound 62
- Mp: amorphous
- IR νmax (cm−1): 3353, 3051, 1598, 1512, 1279, 1109, 1016, 814
- MS m/z (%): 182 (M+, 70), 150(48), 133(22), 124(78), 123(100), 104(21), 77 (33)
- 1H-NMR (CD3COCD3): δ1.17 (2H, m), 2.45 (2H, t, J=7.6 Hz), 3.20 (3H, s), 3.26 (2H, t, J=6.4 Hz), 6.46 (1H, dd, J=8.0, 2.0 Hz), 6.63 (1H, d, J=2.0 Hz), 6.67 (1H, d, J=8.0 Hz), 7.64, 7.70 (each 1H, br s, —OH).
- Compound 63
- Mp: amorphous
- IR νmax (cm−1): 3333, 3051, 1599, 1512, 1279, 1188, 1109
- MS m/z (%): 196 (M+, 63), 150(100), 133(32), 124(73), 123(71), 104(22), 77 (33)
- 1H-NMR (CD3COCD3): δ 1.12 (3H, t, J=7.9 Hz), 1.75 (2H, m), 2.50 (2H, t, J=7.6 Hz), 3.37 (2H, q, J=7.9 Hz), 3.42 (2H, t, J=7.1 Hz), 6.51 (1H, dd, J=8.1, 2.0 Hz), 6.68 (1H, d, J=2.0 Hz), 6.72 (1H, d, J=8.1 Hz).
- Compound 64
- Mp: amorphous
- IR νmax (cm−1): 3351, 3049, 1598, 1512, 1277, 1189, 1112, 950, 789
- MS m/z (%): 210 (M+, 58), 150(100), 133(27), 124(42), 123(63), 104(19), 77 (14)
- 1H-NMR (CD3COCD3): δ 0.88 (3H, t, J=7.4 Hz), 1.53 (2H, sex, J=7.4 Hz), 1.78 (2H, m), 2.51 (2H, t, J=7.6 Hz), 3.32 (2H, t, J=7.4 Hz), 3.35 (2H, t, J=6.4 Hz), 6.51 (1H, dd, J=7.9, 2.0 Hz), 6.69 (1H, d, J=2.0 Hz), 6.73 (1H, d, J=8.0 Hz).
- Compound 65
- Mp: amorphous
- IR νmax (cm−1): 3354, 3051, 1598, 1511, 1277, 1110, 811
- MS m/z (%): 224 (M+, 37), 150(100), 133(20), 132(27), 124(37), 123(52), 104(12), 77 (15)
- 1H-NMR (CDCl3): δ 0.89 (3H, t, J=7.4 Hz), 1.37, 1.50, 1.76 (each 2H, m), 2.50 (2H, t, J=7.4 Hz), 3.34 (2H, t, J=6.6 Hz). 3.36 (2H, t, J=6.4 Hz), 6.50 (1H, dd, J=8.1, 2.1 Hz), 6.68 (1H, d, J=8.1 Hz), 7.68, 7.73 (each 1H, br s, —OH).
- Compound 638A
- Mp: 125-126° C.
- 1H-NMR (CD3COCD3): δ 2.77 (2H, t, J=7.2 Hz), 3.51 (2H, q, J=7.2 Hz), 3.76 (3H, s), 3.78 (3H, s), 6.42, 7.39 (each 1H, d, J=15.6 Hz), 6.74 (1H, dd, J=8.4, 2.0 Hz), 6.81-6.85 (3H, m), 6.91 (1H, dd, J=8.4, 2.0 Hz), 7.05 (1H, d, J=2 Hz).
- 13C NMR: 35.7, 41.4, 55.6, 55.7, 112.2, 113.0, 114.1, 115.6, 118.8, 120.7, 120.9, 127.6, 132.4, 139.9, 145.5, 147.1, 148.0, 149.4, 165.9
- Compound 638B
- Mp: 198° C.
- 1H NMR (400 MHz, CD3COCD3): δ 2.83 (2H, t, J=6.8 Hz), 3.54 (2H, q, J=6.8 Hz), 6.41, 7.40 (each 1H, d, J=16.0 Hz), 6.82 (1H, d, J=8.0 Hz), 6.92 (1H, dd, J=8.0, 1.8 Hz), 7.06 (1 H, d, J=1.8 Hz), 7.20 (2H, d, J=8.0 Hz), 7.44 (2H, d, J=8.0 Hz)
- 13C NMR: δ 35.9, 41.4, 114.7, 116.1, 119.2, 120.2, 121.3, 128.0, 131.6, 132.0, 139.8, 140.6, 146.0, 147.7, 166.6
- Compound 638C
- Mp: 174-177° C.
- 1H NMR (400 MHz, CD3COCD3): δ 2.72 (2H, t, J=7.2 Hz), 3.45 (2H, q, J=7.2 Hz), 6.40, 7.37 (each 1H, d, J=16.2 Hz), 6.73 (2H, d, J=8.4 Hz), 6.80 (1H, d, J=8.4 Hz), 6.90 (1H, dd, J=8.4, 1.6 Hz), 7.03-7.04 (3H, m).
- Compound 638D
- 1H NMR (400 MHz, CD3COCD3): δ 3.75 (3H, s), 4.42 (2H, d, J=6.0 Hz), 6.49, 7.44 (each 1H, d, J=16.0 Hz), 6.81-6.94 (4H, m), 7.07 (1H, d, J=1.6 Hz), 7.25 (2H, dd, J=8.8, 2.4 Hz)
- 13C NMR: δ 43.2, 55.5, 114.4, 114.7, 116.1, 119.3, 121.4, 128.2, 129.6, 132.2, 140.8, 146.0, 147.7, 159.5, 166.4
- Compound 638E
- 1H NMR (400 MHz, CD3COCD3): δ 4.50 (2H, d, J=6.0 Hz), 6.52, 7.46 (each 1H, d, J=15.6 Hz), 6.83 (1H, d, J=8.0 Hz), 6.93 (1H, dd, J=8.0, 1.8 Hz), 7.08 (1H, d, J=1.8 Hz), 7.19-7.34 (5H, m).
- Compound 638F
- 1H NMR (400 MHz, CD3COCD3): δ 3.77 (3H, s), 6.59, 7.66 (each 1H, d, J=16.0 Hz), 6.83-6.88 (3H, m), 6.96 (1H, d, J=8.0 Hz), 7.09 (1H, s), 7.66 (2H, d, J=8.8 Hz).
- Compound 638G
- 1H NMR (400 MHz, CD3COCD3): δ 6.59, 7.53 (each 1H, d, J=15.4 Hz), 6.84 (1H, d, J=8.0 Hz), 6.97 (1H, dd, J=8.0, 2.2 Hz), 7.11 (1H, d, J=2.2 Hz), 7.45 (2H, d, J=8.8 Hz), 7.73 (2H, d, J=8.8 Hz).
- Compound 638H
- 1H NMR (400 MHz, CD3COCD3): δ 6.56, 7.49 (each 1H, d, J=15.6 Hz), 6.77 (2H, d, J=8.8 Hz), 6.83 (1H, d, J=8.0 Hz), 6.96 (1H, dd, J=8.0, 2.0 Hz), 7.08 (1H, d, J=2.0 Hz), 7.56 (2H, d, J=8.8 Hz).
- Compound 6381
- Mp: 174-176° C.
- 1H NMR (400 MHz, CD3COCD3): δ 4.51 (2H, d, J=6.0 Hz), 6.49, 7.44 (each 1H, d, J=16.0 Hz), 6.82 (1H, d, J=8.2 Hz), 6.93 (1H, dd, J=8.2, 2.0 Hz), 6.95-7.00 (1H, m), 7.06 (1H, d, J=2.0 Hz), 7.06-7.16 (2H, m), 7.30-7.36 (1H, m).
- Compound 639A
- Mp: 126-127° C.
- 1H NMR (400 MHz, CD3COCD3); δ 2.88 (2H, t, J=7.2 Hz), 3.65 (2H, q, J=7.2 Hz), 3.87 (3 H, s), 3.88 (3H, s), 6.17, 7.53 (each 1H, d, J=15.6 Hz), 6.82 (1H, d, J=8.4), 6.98 (1H, d, J=2.0 Hz), 7.04 (1H, dd, J=8.4, 2.0 Hz), 7.20-7.33 (5H, m)
- 13C NMR: 36.6, 41.7, 56.0, 56.1, 110.9, 112.4, 120.4, 122.2, 126.8, 128.9, 129.1, 129.3, 129.4, 140.0, 150.2, 151.5, 166.2.
- Compound 639B
- 1H NMR (400 MHz, CD3COCD3): δ 2.27 (3H, s), 2.28 (3H, s), 2.86 (2H, t, J=7.2 Hz), 3.54 (2
- H, q, J=7.2 Hz), 6.37, 7.49 (each 1H, d, J=15.6 Hz), 7.25 (1H, d, J=8.0 Hz), 7.44 (1H, dd, J=8.0, 2.0 Hz), 7.47 (1H, d, J=2.0 Hz), 7.16-7.32 (5H, m).
- Compound 639C
- 1H NMR (400 MHz, CD3COCD3): δ 2.26 (3H, s), 2.85 (2H, t, J=7.2 Hz), 3.54 (2H, q, J=7.2 Hz), 6.49, 7.44 (each 1H, d, J=15.6 Hz), 6.96 (1H, d, J=8.0), 7.04 (1H, s), 7.18 (1H, d, J=8.0 Hz), 7.22-7.32 (5H, m).
- Compound 640
- 1H NMR (400 MHz, CD3COCD3): δ 2.86 (2H, t, J=7.4 Hz), 3.55 (2H, q, J=7.4 Hz), 3.83 (3 H, s), 6.54, 7.49 (each 1H, d, J=15.6 Hz), 6.84 (1H, d, J=8.4), 7.04 (1H, dd, J=8.4, 1.8 Hz), 7.14 (1H, d, J=1.8 Hz), 7.15-7.25 (5H, m).
- Compound 642A
- 1H NMR (400 MHz, CD3COCD3): 3.01 (3H, s), 4.67 (2H, s) 6.97, 7.57 (each 1H, d, J=15.2 Hz), 6.76-6.85 (2H, m), 7.16 (1H, s), 7.26-7.35 (5H, m).
- Compound 642B
- Mp: amorphous
- 1H NMR (400 MHz, CD3COCD3): δ 2.87 (2H, t, J=7.2 Hz), 3.01 (3H, s), 3.53 (2H, t, J=7.2 Hz), 6.68, 7.49 (each 1H, d, J=15.2 Hz), 6.77-6.91 (2H, m), 7.07 (1H, s), 7.22-7.38 (5H, m).
- Compound 642C
- 1H NMR (400 MHz, CD3COCD3): δ 1.79-1.89 (4H, m), 3.44 (2H, t, J=6.8 Hz), 3.66 (2H, t, J=6.8 Hz), 6.70, 7.42 (each 1H, d, J=15.4 Hz), 6.82 (1H, d, J=8.0 Hz), 6.99 (1H, d, J=8.0 Hz), 7.13 (1H, s).
- Compound 642D
- 1H NMR (400 MHz, CD3COCD3): δ 1.54-1.64 (6H, m), 3.53-3.61 (4H, m), 3.66 (2H, t, J=6.8 Hz), 6.82 (1H, d, J=8.2 Hz), 6.96, 7.43 (each 1H, d, J=15.2 Hz), 7.01 (1H, dd, J=8.2, 1.6 Hz), 7.14 (1H, d, J=1.6 Hz).
- The pharmaceutical composition of the present invention could be in the form of a liquid or a patch directly pasting on local wound area with all kinds of excipients, carriers, and diluents if necessary. The formulation can be in the form of pastilles, tablets, and capsules with adding a binder, such as starch or sodium carboxymethyl cellulose according the conventional methods. The formulation also can be in the form of the sustained-release pastilles or capsules by adding the sustained-release reagents. However, the present invention provides a manufacturing process of the present formulation to produce double pastilles or mixture particles with different release level based on the desired particle size, or alternatively to produce an formulation by encapsulating the particle having various size with immediate release film-coated pastilles, slow release film-coated pastilles, and anti-acidity film-coated pastilles.
- The first aspect of the present invention is to provide a compound for preventing or treating the diabetics and the implications thereof, wherein the compound is the catechol-based derivatives. The present invention further provides a pharmaceutical composition which comprises a therapeutically effective amount of the compound and the pharmaceutical acceptable carriers or the excipients.
- Pharmacological Activity
- The pharmacological data of the compounds of the present invention is evaluated in vivo.
- I. Capacities of the Compound to Reduce the Blood Sugar
- (a) Male Wistar rats are provided from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan), each of whose weight is about 200-250 grams, and the average age thereof is above 8 weeks. They were housed under conditions of constant temperature (25±1° C.) and controlled illumination (light time and dark time are respectively 12 hours). Food and water were available.
- (b) Streptozocin-induced type 1 diabetic rats: the male Wistar rats of 8 weeks age undergo a starvation for 72 hours, followed by anaesthetizing the rats by injecting with 30 mg/kg pentobarbital into the abdominal cavity. After the rats fall asleep, 60 mg/kg streptozotocin (STZ) is administrated by an intravenous injection. After a week, phlebotomize and obtain a value of blood sugar by a glucose kit, wherein the glucose kit is further analyzed by Biosystem S.A., Barcelona Spain, BST330. While the value of the blood sugar is greater than 400 mg/dL and the typical three symptoms, eating more, drink more, micturition occur, it is deemed as Type 1 Diabetic rats.
- (c) Insulin-induced type 2 diabetic rats: the abdominal cavity of the male Wistar rats of 12 weeks age are injected with 0.5 IU/kg long-term insulin (MonotardR HM) three times a day for fourteen days. Then, the 10 mg/kg tolbutamide, an anti-diabetic drug of sulfonylurea class, is injected into the abdominal cavity. Phlebotomize 0.1 ml blood respectively at the preadministration and the postadministration of sixty minutes, and calculate the reduced value of the blood sugar. If the variation of the ability of lowering blood sugar is less than 10%, which is deemed as the type II (insulin resistance) diabetes rat.
- (d) The administration: Dissolve the medicine equivalently in deionized water, and then administrate the mentioned solution into the normal and diabetic rats by an orally perfusion. Keep with the desired concentration of the perfusion amount by taking suitable amount of the medicine solution according to the weight of the different animal.
- (e) Detection of the Blood Sugar
- The rats to be experimented should undergo a starvation for 8-12 hours overnight. Next day, the rats are anesthetized with 30 mg/kg pentobarbital by injecting into the abdominal cavity. After the rats fall asleep, fix the rats on the board with the rubber band. Open the groin, find the veins, bleed 0.1 ml blood from an empty stomach, and then feed the medicine into the body of the rats by taking orally. After 90 minutes, bleed and perform a centrifugation (13,000 rpm, 5 minutes) to separate the serum and the plasma. Take the 10 μl supernatant of the serum and add 1 ml reagent of the glucose kit thereinto by gently mixing. React for 5 minutes at 37° C., followed by detecting the value of the blood sugar by means of BST330 based on the different absorption level. The principal of the glucose kit depends on the level of the glucose being oxidized into glucuronic acid and hydrogen peroxide, which exhibits different levels of red color. The value of the blood sugar (mg/dL) is calculated by comparing the level of redness with contrasting the standard curve.
- (f) Calculation for percentage of lowering blood sugar
-
(The value of blood sugar at postadministration)−(The value of blood sugar at preadministration)/(The value of blood sugar at preadministration)×100% - (g) Statistical Method
- The results of the experiments are presented in the average value±the standard error (mean±SE), and the variations therebetween are evaluated according to the Student's t-test, while the variations thereamong are evaluated according to one-way ANOVA and Bonferroni's t-test, wherein P<0.05 is deemed to have apparent differences.
- II. The Evaluations of the Compound on Flow Rate of the Coronary Artery
- (h) The Evaluations on the Flow Rate of the Coronary Artery
- Each of the male Wistar rats weighs about 200-250 grams, and is anesthetized with 25 mg/kg pentobarbital and 16 mg/kg heparin by injecting into the abdominal cavity. After falling asleep, separate the cervical vertebra and immediately take the heart out hanging on the constant pouring pressure circulation instrument (Langendorff, AD Instruments Pty Ltd, ML870B2) and fill a 37° C. pouring solution of 95% of oxygen and 5% of carbon dioxide with the artery (119.7 mM NaCl, 23.8 mM NaHCO3, 5.6 mM glucose, 1.2 mM CaCl2, 1.1 mM MgCl2, 0.3 mM NaH2PO4, and 5.0 mM KCl), which washes the heart and clean out the blood water by pouring in a reverse direction. The rate of the reverse pouring is 10 ml/min, followed by maintaining the pouring pressure of the coronary artery at 80 mmHg. After balancing for thirty minutes, measure the rate of the pouring solution flowing in the heart, and observe the change of the rate the pouring solution flowing in the heart while the testing drug is added.
- (i) The coronary artery ligature of the living rat—the heart protective evaluations at the reperfusion model.
- The grown-up male rats having the weight of 250˜300 grams (Sprague-Dawley strain, purchased BioLASCO Taiwan Co., Ltd.) are anesthetized with 1.25 g/kg urethane by the abdominal cavity injection. After anaesthetization, cut the trachea, connect with the artificial respirator (Harvard Rodent Ventilator Model 983), give 15 ml/kg of the tidal volume, and control the respiratory rate at 668 strokes/min, followed by cutting off both sides of the vagus immediately. After the intubation of the right arterial carotis, it is connected to the pressure converter (Statham P23XL transducer) so as to monitor the changes of systemic blood pressure. In addition, the rats' four limbs are connected to the silver electrode, so as to record the changes of the electrocardiogram (ECG). Blood pressures, heartbeats and electrocardiogram curves are recorded and analyzed by the software (MacLab data acquisition system, AD Instrument Pty, Castle Hill, NSW, Australia).
- After all previous preparations have been done, open the ribcage by the thoracotomy and cut off the skin layers and muscles to find the rib. Burn the fourth and fifth rib close to 2 mm of the sternum in an electrical knife and stabilize the injury with the retractor followed by rending the pericardial membrane, separating the left atrial appendage gently by the cottons, and clasping the anterior interventricular branch of the left coronary artery immediately between the left atrial appendage and the pulmonary artery by a needle forceps having a silk yarn with a hook. Put loops on both ends of silk yarn to seal the wound by unclamping the retractor. Balance in 15 minutes, and if there exists cardiac arrhythmia or the systolic pressure is lower than 80 mmHg, it will be eliminated.
- After the balance, the acute cardiac muscle ischaemia is caused by pushing the loop passed by a silk yarn with a hemostat downwards to be stabilized. Then, unclamp the hemostat and uplift the loop to perform a reperfusion of the coronary artery being ligated by the silk yarn. While the flow of the coronary artery is successively blocked, the ischaemic area should appear the cyanosis, where some indicators of the cardiac ischaemia could be observed, including the lowering pressure of the coronary artery and the changed electrocardiography (R wave broadens, and ST section raises), which is achieved by means of the same strength of pushing downwards during each surgery. If the same surgical procedure is performed, the rat without administrating the drug and performing an ischaemia and an ischaemia/reperfusion is regarded as the sham group. The rundown of the ischaemia and the ischaemia/reperfusion of the present test are as follows.
- Perform an ischaemia for 45 minutes and perform an ischaemia/reperfusion for 2 hours. Administrate by injecting the drug into the adnominal cavity after perform the ischaemia for 15 minutes.
- (i-1) Detection of the Heart Intract Size
- If the rat does not die from the cardiac arrhythmia, push the loop downwards again to block the blood flow after the reperfusion is finished. Inject the approximately 2 ml, 1% methylene blue into the ischaemic area via a jugular vein, where the non-ischemic area is dyed as purple and the ischemic area or area at risk is retained as red. Subsequently, the heart is immediately took out and washed by the physiological salt solution to remove the connective tissue of the atrium and the surplus water. Cut the undyed ischemic area and weight the total ventricle to calculate the ischemic area of the ventricle.
-
Area at risk (% of total ventricular)=(Weight of risk area)/(Total ventricular weight)×100%. - Cut the ischemic area into a slice with the thickness of approximately 1 mm. Immerse the slice into a TTC (2,3,5-triphenyltetrazolium chloride, in saline) solution, and heat the resultant solution at the 37° C. incubator for 30 minutes, followed by replacing the solvent with 10% formaldehyde solution to preserve the resulting solution for two weeks. The living cells are able to produce the dehydrogenase, which could reduce TTC to a crimson formazan precipitate, whereas the dead cells are unable to produce dehydrogenase, which decolor the formazan as a gray precipitate. Cut and weight the gray infraction area and calculate the ratio.
-
Infract Size (% of risk area)=(Weight of infraction)/(Weight of risk area)×100%. - Please refer to Table 10, which shows the result of the changes of blood sugar in the treatment of the compound 370G among the normal rats and the diabetic rats. This test is performed by orally administrating the compound 370G. It is found that the phenomenon of reducing the blood sugar are shown on the normal rats and the type II diabetics rats when they are orally administrated the compound 370G a catechol-based derivative, with the dosage ranging from 0.05 to 1.0 mg/kg, wherein *P is smaller than 0.05 and the blank solution is orally administrated as a control contrast.
-
TABLE 10 Normal rats Type 2 diabetic rats Type 1 diabetic rats % decrease % decrease % decrease 370G (45) in plasma in plasma in plasma (mg/kg) glucose n glucose n glucose n Vehicle 5.8 ± 5.7 8 2.6 ± 1.2 8 0.6 ± 0.1 8 (control) 0.01 11.4 ± 3.1 8 — — — — 0.05 32.0 ± 1.1 * 8 7.4 ± 2.6 5 — 0.1 32.9 ± 2.3 * 7 17.2 ± 2.6 * 5 11.8 ± 5.5 * 5 0.5 32.8 ± 3.4 * 6 20.1 ± 3.4 * 6 13.8 ± 4.3 * 6 1.0 29.5 ± 1.7 * 6 23.3 ± 3.3 * 8 11.6 ± 1.7 * 8 - Please refer to Table 14, which shows the comparative result of the changes of blood sugar in the treatment of the compound 370G at the preadministration and the postadministration. It is found that the compound 370 G has the strongest effect for reducing the blood sugar on the normal rat while having the weakest effect on the type I diabetic rat. Please refer to Table 11, which shows the result of the changes of the insulin's concentration in the treatment of the compound 370G at the preadministration and the postadministration. After orally administrating the compound 370G with the dosage of 1.0 mg/kg, the secretion of insulin can be increased in 60 minutes (*P<0.05), which suggested that the compound 370G for reducing the blood sugar may be associated with enhancement of the secretion of insulin. However, it is also observed that the dominant effect for reducing the blood sugar on the type I diabetic rats, which are incapable of secreting insulin. Therefore, it is suggested that the compound 370G for reducing the blood sugar involves another kind of mechanism associated with the blood sugar reduction in addition to enhance the release of insulin.
-
TABLE 11 370G (45) (1 mg/kg, p.o.) Pre-treatment Post-treatment(30 min) Insulin (μIU/ml) 7.7 ± 1.0 14.9 ± 3.4 * -
TABLE 14 Pre-treatment Post-treatment Catechol Plasma Plasma Derivatives glucose glucose % decrease in (0.5 mg/kg) (mg/dL) (mg/dL) plasma glucose n Vehicle (control) 138.5 ± 5.9 129.3 ± 2.2 5.8 ± 5.7 8 639B 116.7 ± 2.8 84.0 ± 5.0 # 28.1 ± 3.3 * 3 371G 108.0 ± 4.2 76.7 ± 1.8 # 28.8 ± 3.3 * 3 370G (45) 120.5 ± 5.3 81.0 ± 5.7 # 32.8 ± 3.4 * 6 639C 104.2 ± 9.9 83.4 ± 3.9 19.3 ± 4.1 5 370D 90.7 ± 3.6 74.9 ± 3.6 # 17.5 ± 1.9 7 638B 98.1 ± 5.2 76.8 ± 4.1 # 21.4 ± 3.0 * 8 638A 102.5 ± 2.4 83.6 ± 1.9 # 18.1 ± 2.9 8 615 (37) 138.3 ± 4.1 105.2 ± 3.5 # 23.9 ± 2.1 * 6 - Please refer to Table VI, which shows the result of the changes of blood sugar respectively in the treatment of the compound 370G and Rosiglitazone. Rosiglitazone is a kind of insulin sensitizer. The compound 370G and Rosiglitazone are orally administrated into the type II diabetic rats for 90 minutes, and then detect the plasma glucose concentration. It is found that the type II diabetic rats having the insulin impedance have the similar effect for reducing the blood sugar with the commercial insulin sensitizer.
-
TABLE VI Treatment % decrease in plasma glucose n Rosiglitazone (1 mg/kg, p.o.) 15.6 ± 6.3 8 370G (45) (0.5 mg/kg, p.o.) 20.0 ± 7.7 8 - Please refer to
FIG. 1 , which shows the result of the changes of the intravenous glucose tolerance test (IGTT) in the treatment of the compound 370G. It is found that the glucose availability of the rats is raised in the oral administration of the compound 370G with the dosage of 0.5 mg/ml/kg as compared the results of the control contrast (*P<0.05), which is administrated with 1000 mg/kg glucose for 30 minutes by an intravenous injection. - Please refer to Table 13, which shows the result of the survival rate after orally administrating the compound 370G into the type I diabetic rats. Table 13 is a safety evaluation, wherein the type I diabetic rats are respectively orally administrated with the compound 370G at the dosage of 10 mg/kg and 30 mg/kg. After seven days, it is found that the administration of the compound 370G at the respective dosage of 10 mg/kg and 30 mg/kg do not affect the survival rate of the rats.
-
TABLE VII 370G (45)Treatment Survival rate (%) of rats n 10 mg/kg, p.o. 100% 4 30 mg/kg, p.o. 100% 4 - In comparison with the ability of other compounds of catechol-based derivatives for reducing the blood sugar, wherein the results shown in Table 14, it is found that these compounds are dominant on reducing the blood sugar after the oral administration of the catechol-based derivatives. The statistics of *P<0.05 means the distinguishable variation as compared with the control contrast, and the statistics of *P<0.05 means the distinguishable variation as compared with the pre-treatment contrast.
- The present compounds of the catechol-based derivatives exhibit good effect on reducing the blood sugar for the normal and the diabetic rats at the lower dosages ranging from 0.05 to 1 mg/kg, whereas the survival rate of the above rats are not influenced at the higher dosages of respective 10 mg/kg and 30 mg/kg. Therefore, this kind of catechol-based derivatives could be developed to be a potential anti-diabetics drug.
- The second aspect of the present invention is to provide a catechol-based derivative for preventing and/or treating ischemia and the complication thereof, and to provide a pharmaceutical composition comprising the above derivative, including the therapeutically effective amount of the catechol-based derivative selected form the group consisting of the formula (I) and a pharmaceutical acceptable carrier or an excipient.
- Please refer to Table 15 and 16, which respectively show the result of the coronary flow rate in the treatment of the catechol-based derivatives. It is found that the respective compound 370G, 638J, 640, 6381, 642A, 642B, 639B, and 639C are capable of increasing the coronary flow rate of Wistar rats, which suggests that this kinds of catechol-based derivatives are capable of increasing the coronary flow rate and reducing the injury areas of cardiac muscles resulting from the myocardial ischemia-reperfusion.
-
TABLE 15 conc. coronary flow (ml/min) μM) 370G (45) n 638H n 640 n 638I n 0 11.8 ± 1.0 5 9.0 ± 0.3 3 9.7 ± 1.3 4 7.4 ± 0.7 3 0.1 12.4 ± 1.1 5 9.0 ± 0.5 3 10.1 ± 1.5 4 7.1 ± 0.5 3 0.3 13.2 ± 1.4* 5 8.9 ± 0.5 3 10.2 ± 1.4 4 7.1 ± 0.5 3 1 15.6 ± 1.2* 5 9.1 ± 0.5 3 10.3 ± 1.5 4 7.6 ± 0.8 3 3 17.4 ± 1.3* 5 10.1 ± 0.7 3 11.0 ± 1.5* 4 8.2 ± 0.8 3 10 19.5 ± 0.7* 4 13.1 ± 1.0* 3 14.6 ± 2.2* 4 9.3 ± 0.7* 3 -
TABLE 16 conc. coronary flow (ml/min) μM) 642A n 642B n 639B n 639C n 0 10.0 ± 0.7 3 9.8 ± 2.1 3 7.4 ± 0.2 3 11.9 ± 2.0 3 0.1 12.9 ± 0.4* 3 9.8 ± 2.1 3 0.3 14.2 ± 0.8* 3 10.4 ± 1.7 3 1 16.8 ± 1.6* 3 12.8 ± 1.9 3 9.0 ± 0.4* 3 13.5 ± 1.5 3 3 19.8 ± 2.1* 3 17.4 ± 1.9* 3 11.6 ± 0.6* 3 17.2 ± 1.8* 3 10 23.2 ± 1.7* 3 - Please refer to
FIG. 2 , which shows the results of the ischemic areas at risk after the coronary artery is ligated. The coronary artery of the rat heart is ischaemic by ligating for 45 minutes, and the blood vessel is unclamped for the reperfusion for two hours, wherein some tissues of the local ischemic area will be deteriorated. After comparing the respective ratio of the areas at risk in the overall area between the control contrast that orally administrated with DMSO and PEG solvents and the trial tests that orally administrated with the compound 370G at the dosages of respective 10−6 mg/kg, 10−5 mg/kg, and 15 mg/kg, it is found that the ratio variations thereof are non-obvious. (The ratio in the treatment of DMSO, PEG, and the compound 370G at the dosages of 10−6 mg/kg, 10−5 mg/kg, and 15 mg/kg are respectively 38.7±1.0%, of 36.4+1.3%, of 39.1±1.9%, 36.7±2.3%, and 41.1±1.3%). - Please refer to
FIG. 3 , which shows the ratios of the cardiac infract size in the treatment of 370G at the different dosages. The ratio of both DMSO and PEG, which serve as the contrast agents, are respectively 80.2+1.2% and 80.1±1.0%. Surprisingly, the infract size is reduced to 70.9±2.8 in the oral administration of the compound 370G at the dosage of 10−6 mole/kg (approximately 0.28 mg/kg); the infract size is reduced to 68.8±2.9% in the oral administration of the compound 370G at the dosage of 10−5 mole/kg (approximately 2.8 mg/kg); and the infract size is reduced to 62.8±1.8% in the oral administration of the compound 370G at the dosage of 15 mole/kg. Therefore, the mentioned results show the distinguishable variation as compared with the contrast agents, wherein * represents p<0.05, ** represents p<0.01, and *** represent p<0.001). - Please refer to Table 15 and 16 again. In the animal tests of the coronary artery ligature and the reperfusion, it is found that in the treatment of the coronary artery ligature for 45 minutes and the reperfusion for two hours, the infract size of cardiac injury areas could be reduced by orally administrating with the catechol-based derivatives after performing the coronary artery ligature for 15 minutes. The Table 15 and 16 show that the respective compounds 370G, 638J, 640, 6381, 642A, 642B, 639B, and 639C are capable of increasing the coronary flow rate. Therefore, it is suggested that the respective compounds 638J, 640, 638I, 642A, 642B, 639B, and 639C have the similar effect of the compound 370G for preventing the heart or other tissues damaging resulting from the myocardial infraction.
- In view of the above experimental results, the catechol-based derivatives of the present invention are indeed capable of preventing or treating the diabetics and the ischaemic diseases and the implications thereof.
- While the invention has been described with reference to the above examples, it is to be understood that the invention needs not be limited to the disclosed embodiments. On the contrary, it is intended to cover various modifications and similar arrangements included within the spirit and scope of the appended claims which are to be accorded with the broadest interpretation so as to encompass all such modifications and similar structures.
Claims (5)
1. A catechol-based derivative being one of a compound of a formula (I) and a pharmaceutically acceptable salt thereof,
wherein R1 and R2 are independently selected from the group consisting of H, —OR, —NO2, —NH2, and a halogen;
R in the —OR is one selected from the group consisting of H, (C1-C6)alkyl, (CH2)nPh, SO3″ and Ar;
R3 is one of O and S;
R4 is N;
X and Y are selected from the group consisting of alkyl, alkenyl, alkynyl, and —OCH2—;
R5 is one selected from the group consisting of H, (C1-C15)alkyl, (CH2)nAr and Ar, wherein the n is an integer from 1 to 3; and
R6 is one of H and (C1-C6) alkyl.
3. The catechol-based derivative as claimed in claim 2 , wherein Ar is capable of being substituted by one selected from the group consisting of
4. A pharmaceutical composition for treating diabetes, comprising a catechol-based derivative of claim 1 and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.
5. A pharmaceutical composition for treating an ischemia, comprising a catechol-based derivative of claim 1 and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/114,835 US20110224260A1 (en) | 2006-08-07 | 2011-05-24 | Catechol-based derivatives for treating or preventing diabetics |
US13/333,681 US20120094973A1 (en) | 2006-08-07 | 2011-12-21 | Catechol-based derivatives for treating or preventing diabetics |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2006/001991 WO2008028314A1 (en) | 2006-08-07 | 2006-08-07 | Catechol derivatives, composition and application thereof |
US12/368,167 US8088818B2 (en) | 2006-08-07 | 2009-02-09 | Catechol-based derivatives for treating or preventing diabetics |
US13/114,835 US20110224260A1 (en) | 2006-08-07 | 2011-05-24 | Catechol-based derivatives for treating or preventing diabetics |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/368,167 Division US8088818B2 (en) | 2006-08-07 | 2009-02-09 | Catechol-based derivatives for treating or preventing diabetics |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/333,681 Division US20120094973A1 (en) | 2006-08-07 | 2011-12-21 | Catechol-based derivatives for treating or preventing diabetics |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110224260A1 true US20110224260A1 (en) | 2011-09-15 |
Family
ID=39156788
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/368,167 Active 2026-09-03 US8088818B2 (en) | 2006-08-07 | 2009-02-09 | Catechol-based derivatives for treating or preventing diabetics |
US13/114,835 Abandoned US20110224260A1 (en) | 2006-08-07 | 2011-05-24 | Catechol-based derivatives for treating or preventing diabetics |
US13/333,681 Abandoned US20120094973A1 (en) | 2006-08-07 | 2011-12-21 | Catechol-based derivatives for treating or preventing diabetics |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/368,167 Active 2026-09-03 US8088818B2 (en) | 2006-08-07 | 2009-02-09 | Catechol-based derivatives for treating or preventing diabetics |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/333,681 Abandoned US20120094973A1 (en) | 2006-08-07 | 2011-12-21 | Catechol-based derivatives for treating or preventing diabetics |
Country Status (2)
Country | Link |
---|---|
US (3) | US8088818B2 (en) |
WO (1) | WO2008028314A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11491117B2 (en) * | 2017-10-04 | 2022-11-08 | Sorbonne Université | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2758016A1 (en) * | 2008-06-05 | 2009-12-10 | Novotyr Therapeutics Ltd. | Novel modulators of protein kinase signaling |
EP2179984A1 (en) * | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
US7893736B2 (en) * | 2008-11-14 | 2011-02-22 | Analog Devices, Inc. | Multiple input PLL with hitless switchover between non-integer related input frequencies |
JP2012524816A (en) * | 2009-04-23 | 2012-10-18 | インバスク・セラピユーテイクス・インコーポレイテツド | Compositions and methods for the treatment of cardiovascular disease |
GB0909768D0 (en) * | 2009-06-08 | 2009-07-22 | Nanyang Polytechnic | Novel compounds and uses thereof |
PL2519100T3 (en) | 2009-12-29 | 2017-09-29 | Mapi Pharma Limited | Intermediate compounds and processes for the preparation of tapentadol and related compounds |
TW201244722A (en) * | 2011-05-03 | 2012-11-16 | Univ Nat Taiwan | Drugs and pharmaceutical composition used in prevention or treatment chronic heart disease |
CN102850317B (en) * | 2011-06-27 | 2017-02-08 | 天士力制药集团股份有限公司 | Substituted cinnamide derivative, its preparation method and application |
KR101624340B1 (en) * | 2013-01-18 | 2016-05-25 | 충북대학교 산학협력단 | Novel Chlorogenic Acid Derivatives and Composition for Treating Inflammatory Disease Comprising the Same |
EP3021944B1 (en) | 2013-07-14 | 2018-12-19 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases |
CN105646439A (en) * | 2014-11-10 | 2016-06-08 | 中国人民解放军第二军医大学 | Synergist for antifungal drugs, and preparation and application thereof |
AU2016213972B2 (en) | 2015-02-05 | 2020-07-09 | Tyrnovo Ltd. | Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer |
WO2019004492A1 (en) * | 2017-06-26 | 2019-01-03 | 한국식품연구원 | Composition for preventing or treating obesity or lipid-related metabolic diseases containing acrylamide-based compounds as active ingredients |
WO2019120235A1 (en) * | 2017-12-22 | 2019-06-27 | 中国科学院上海药物研究所 | Class of phenylcarboxylic acid derivatives, preparation method therefor and use thereof |
WO2023064783A1 (en) * | 2021-10-11 | 2023-04-20 | The Johns Hopkins University | Dopa and caffiec acid analogs as novel gcpii inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232923A (en) * | 1988-03-18 | 1993-08-03 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives and pharmaceutical preparations containing same |
-
2006
- 2006-08-07 WO PCT/CN2006/001991 patent/WO2008028314A1/en active Application Filing
-
2009
- 2009-02-09 US US12/368,167 patent/US8088818B2/en active Active
-
2011
- 2011-05-24 US US13/114,835 patent/US20110224260A1/en not_active Abandoned
- 2011-12-21 US US13/333,681 patent/US20120094973A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11491117B2 (en) * | 2017-10-04 | 2022-11-08 | Sorbonne Université | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity |
Also Published As
Publication number | Publication date |
---|---|
WO2008028314A1 (en) | 2008-03-13 |
US20120094973A1 (en) | 2012-04-19 |
US20090143397A1 (en) | 2009-06-04 |
US8088818B2 (en) | 2012-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8088818B2 (en) | Catechol-based derivatives for treating or preventing diabetics | |
KR101274981B1 (en) | Biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
JP3806431B2 (en) | Substituted benzoylguanidines and their preparation | |
TW504505B (en) | Substituted 1-oxo-1,2-dihydroisoquinolinoylguanidines and 1,1-dioxo-2H-1,2-benzothiazinoylguanidines, a process for their preparation, and a pharmaceutical composition containing them | |
JPH07109251A (en) | Ortho-substituted benzoylguanidine, its production, its use as medicine or diagnostic preparation, and medicine containing it | |
TW415936B (en) | Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
US6737423B2 (en) | Substituted heterocyclo-norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | |
JP4991537B2 (en) | Cis-1,2-substituted stilbene derivatives and their use in the manufacture of a medicament for the treatment and / or prevention of diabetes | |
US8722701B2 (en) | 1,2,3,4,5 6,7,8-octohydro-9-phenylacetamidoacridine, the preparation method and medical use thereof | |
US20090161561A1 (en) | Method and system for determining characters of channels | |
CN111840112A (en) | Application of carnosic acid or derivatives thereof in preparing medicine for treating diabetic complications | |
US20230218563A1 (en) | Methods for treating or preventing chronic kidney disease | |
JPH0931045A (en) | 4-fluoroalkylated benzoylguanidine, its production, its use as medicine or diagnostic drug, and medicine containing it | |
RU2159762C2 (en) | Substituted benzoyl guanidines, method of preparing thereof, inhibition method, and pharmaceutical agent | |
CN111393421A (en) | Butenolide derivative and preparation method and application thereof | |
EP1827425B1 (en) | Use of ppar agonists for the treatment of congestive heart failure | |
JP2954989B2 (en) | Treatment of diabetes mellitus with bisphenol derivatives | |
US6518450B2 (en) | Guaiacoxypropanolamines with alpha/beta adrenergic blocking activity | |
CN113197907B (en) | Application of gardenia acetic acid and derivatives thereof in preparing medicine for treating diabetes | |
WO2024027521A1 (en) | Methylophiopogonone a derivative, and preparation and use thereof | |
JP4039586B2 (en) | Ortho-substituted benzoylguanidines, processes for their preparation, their use as medicaments or diagnostics and medicaments containing them | |
CN118255686A (en) | Fluorine-containing trans-phenyl cyclopropylamine derivative, and preparation method and application thereof | |
CN116473953A (en) | Application of caffeic acid glyceride compounds in preparation of medicines or functional foods | |
TW200812566A (en) | Catechol-based derivatives for treating or preventing diabetics | |
JPS6176441A (en) | Novel ascochlorin derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |